fluconazole and Mycoses studies

Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.

Research Excerpts

Excerpt	Relevance	Reference
"The results of a pharmacoeconomic study of the cost-effectiveness of posaconazole versus fluconazole in preventing invasive fungal infections (IFIs) in patients with graft-versus-host disease (GVHD) are reported."	9.16	Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease. ( Langston, AA; O'Sullivan, AK; Pandya, A; Papadopoulos, G; Perfect, JR; Thompson, D; Weinstein, MC, 2012)
" The authors conducted the first prospective, randomised controlled trial of nystatin compared with fluconazole for the prevention of fungal colonisation and invasive fungal infection in very low birth weight (VLBW) neonates."	9.15	Randomised controlled trial of prophylactic fluconazole versus nystatin for the prevention of fungal colonisation and invasive fungal infection in very low birth weight infants. ( Akar, M; Aydemir, C; Dilmen, U; Dizdar, EA; Erdeve, O; Oguz, SS; Sarikabadayi, YU; Saygan, S, 2011)
"We audited the effect of co-prescription of daily oral fluconazole with antibiotics in the Pan Thames centres on fungal peritonitis."	9.15	Does antifungal prophylaxis with daily oral fluconazole reduce the risk of fungal peritonitis in peritoneal dialysis patients? The Pan Thames Renal Audit. ( Davenport, A; Wellsted, D, 2011)
" Cefpirome was administered as prophylaxis against bacterial infection, and meropenem+minocycline as an empiric window therapy for febrile neutropenia."	9.14	[Comparison of micafungin and fosfluconazole as prophylaxis for invasive fungal infection during neutropenia in children undergoing chemotherapy and hematopoietic stem cell transplantation]. ( Higuchi, B; Hirano, S; Inoue, M; Ishihara, T; Kawa, K; Kondo, O; Kouroki, M; Koyama, M; Sakata, A; Sakata, N; Sawada, A; Takeshita, Y; Yasui, M; Yoshioka, A, 2009)
"5 mg/kg twice daily; N=248) with fluconazole oral solution or capsules (400 mg daily; N=246) in 494 patients with anticipated profound neutropenia (i."	9.12	An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. ( Andreesen, R; Bertz, H; Bodenstein, H; Boewer, C; Cornely, O; Dölken, G; Glasmacher, A; Hänel, M; Junghanss, C; Pasold, R; Ullmann, AJ; Wandt, H; Wedding, U; Wolf, HH, 2006)
"In an international, randomized, double-blind trial, we compared oral posaconazole with oral fluconazole for prophylaxis against invasive fungal infections in patients with graft-versus-host disease (GVHD) who were receiving immunosuppressive therapy."	9.12	Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. ( Boparai, N; Chandrasekar, P; Durrant, S; Greinix, H; Langston, A; Lipton, JH; Morais de Azevedo, W; Patino, H; Pedicone, L; Reddy, V; Tarantolo, SR; Ullmann, AJ; Vesole, DH, 2007)
"In patients undergoing chemotherapy for acute myelogenous leukemia or the myelodysplastic syndrome, posaconazole prevented invasive fungal infections more effectively than did either fluconazole or itraconazole and improved overall survival."	9.12	Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. ( Angulo-Gonzalez, D; Cornely, OA; Goh, YT; Hardalo, C; Helfgott, D; Holowiecki, J; Maertens, J; Perfect, J; Petrini, M; Stockelberg, D; Suresh, R; Ullmann, AJ; Walsh, TJ; Winston, DJ, 2007)
"We performed a randomized, controlled study comparing the prophylactic effects of capsule forms of fluconazole (n = 110) and itraconazole (n = 108) in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) during and after chemotherapy."	9.12	The prophylactic effect of itraconazole capsules and fluconazole capsules for systemic fungal infections in patients with acute myeloid leukemia and myelodysplastic syndromes: a Japanese multicenter randomized, controlled study. ( Aoyama, Y; Ito, Y; Kanamaru, A; Kiguchi, T; Masaoka, T; Matsuda, M; Matsuura, Y; Mugitani, A; Ohyashiki, K; Sakamoto, E; Takeuchi, M; Tamura, K; Urabe, A; Wakita, H; Yoshida, I, 2007)
"We hypothesized that chemoprophylaxis with the echinocandin micafungin would be an effective agent for antifungal prophylaxis during neutropenia in patients undergoing hematopoietic stem cell transplantation (HSCT)."	9.11	Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. ( Bunin, N; Hiemenz, JW; Lee, JM; Lipton, JH; Miller, CB; Ratanatharathorn, V; Satoi, Y; Stepan, DE; van Burik, JA; Vesole, DH; Wall, DA; Walsh, TJ, 2004)
"A pilot exploratory study was undertaken to collect preliminary information relating to safety and overall outcome in using intravenous fluconazole (FLUC) for managing antibiotic resistant neutropenic fever (ARNF), with the objective of assessing feasibility of performing a larger prospective controlled study."	9.08	Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever--preliminary observations from a pilot, exploratory study. ( Baillie, F; Clink, H; Ellis, ME; Ernst, P; Greer, W; Halim, MA; Kalin, M; Spence, D, 1995)
"Amphotericin B, despite its intrinsic servere toxicity, is the most commonly used empirical antifungal therapy in cancer patients with unexplained fever not responding to empirical antibacterial therapy."	9.08	Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. ( Caselli, D; Castagnola, E; Congiu, M; Fanci, R; Garaventa, A; Giacchino, M; Menichetti, F; Moroni, C; Rossi, MR; Van Lint, MT; Viscoli, C, 1996)
"We randomly assigned 106 patients with absolute neutropenia (< or = 500 cells microL) and persistent fever of undetermined origin (> 38 degrees C) despite 1 week of broad-spectrum antibiotic therapy to receive either fluconazole 400 mg orally daily or amphotericin B 0."	9.08	A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. ( Aziz, Z; Khan, S; Malik, IA; Moid, I; Suleman, M, 1998)
"To compare the efficacy and tolerability of fluconazole and oral amphotericin B in preventing fungal infection in neutropenic patients with acute leukemia."	9.07	Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. ( Barbui, T; Bucaneve, G; Carotenuto, M; D'Antonio, D; Del Favero, A; Fasola, G; Liso, V; Mandelli, F; Martino, P; Menichetti, F; Micozzi, A; Nosari, AM; Ricci, P, 1994)
"An open, randomized study was performed at 18 European centres to compare the efficacy, safety and tolerance of oral fluconazole with oral polyenes for the prophylaxis of fungal colonization and infection in adults at high risk of developing neutropenia."	9.07	Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group. ( Brammer, KW; Ehninger, G; Mufti, GJ; Philpott-Howard, JN; Wade, JJ, 1993)
"Prophylactic fluconazole prevents colonization and superficial infections by Candida species other than Candida krusei in patients undergoing chemotherapy for acute leukemia and is well tolerated."	9.07	Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. ( Buell, DN; Chandrasekar, PH; Goodman, JL; Ho, WG; Horowitz, H; Islam, MZ; Lazarus, HM; Rosenfeld, CS; Shadduck, RK; Silber, JL; Winston, DJ, 1993)
"Eighty-eight immunocompetent patients with deep mycoses from eight countries were evaluated with the same protocol for efficacy of fluconazole monotherapy."	9.07	A Pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. Pan-American Study Group. ( Arathoon, EG; Borelli, D; Bran, JL; Castro, LG; Diaz, M; Franco, L; Montero-Gei, F; Negroni, R; Restrepo, A; Sampaio, SA, 1992)
"To compare the benefits and harms of voriconazole with those of amphotericin B and fluconazole when used for prevention or treatment of invasive fungal infections in cancer patients with neutropenia."	8.90	Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia. ( Dalbøge, CS; Gøtzsche, PC; Johansen, HK; Jørgensen, KJ, 2014)
" Terms such as micafungin, aspergillosis, zygomycosis, invasive fungal infections, emerging fungal infections, antifungal treatment or therapy, antifungal prophylaxis, empiric or pre-emptive therapy were crossed."	8.85	[Future role of micafungin in the treatment of invasive mycoses caused by filamentous fungi]. ( Salavert-Lletí, M; Zaragoza-Crespo, R, 2009)
"To compare the benefits and harms of voriconazole with those of amphotericin B and fluconazole when used for prevention or treatment of invasive fungal infections in cancer patients with neutropenia."	8.83	Voriconazole versus amphotericin B in cancer patients with neutropenia. ( Gøtzsche, PC; Johansen, HK; Jørgensen, KJ, 2006)
"Fluconazole is compared with other agents for antifungal prophylaxis in patients with chemotherapy-induced neutropenia."	8.79	Fluconazole for antifungal prophylaxis in chemotherapy-induced neutropenia. ( Briceland, LL; Preston, SL, 1995)
"Fluconazole is a novel triazole antifungal drug chiefly used in the treatment of opportunistic mycoses in immuno-compromised patients, particularly those with the acquired immuno-deficiency syndrome (AIDS)."	8.78	Fluconazole. Review and situation among antifungal drugs in the treatment of opportunistic mycoses of human immuno-deficiency virus infections. ( Lafaix, C; Patey, ON; Vincent-Ballereau, FN, 1991)
"To evaluate the cost-effectiveness of solid oral tablets of posaconazole versus fluconazole capsules for the prophylaxis of IFDs in allogeneic HSCT recipients with graft-versus-host disease (GVHD) in Spain."	7.88	Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. ( Aragón, B; Cámara, R; Gozalbo, I; Grau, S; Jurado, M; Sanz, J, 2018)
"Posaconazole prophylaxis during induction chemotherapy for acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) has been shown to significantly decrease the incidence of invasive fungal disease (IFD) and increase overall survival in a trial setting, but only small real-life studies have been published."	7.83	Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes. ( Björkholm, M; Blennow, O; Cederlund, K; Dahlén, T; Kalin, M; Ljungman, P; Nordlander, A, 2016)
"Posaconazole is superior to fluconazole/itraconazole in preventing invasive fungal diseases (IFDs) in neutropenic patients."	7.83	Posaconazole vs fluconazole or itraconazole for prevention of invasive fungal diseases in patients with acute myeloid leukemia or myelodysplastic syndrome: a cost-effectiveness analysis in an Asian teaching hospital. ( Chan, TS; Gill, H; Hwang, YY; Kwong, YL; Marcella, SW, 2016)
"In this retrospective review, we examined the incidence of FP in a cohort of 115 patients, who had received antibiotics for bacterial peritonitis and received a co-prescription of fluconazole, 50 mg/day for the duration of antibiotic therapy."	7.76	Prophylaxis against fungal peritonitis in CAPD--a single center experience with low-dose fluconazole. ( Antony, SK; Gandhe, S; Nayak, KS; Prabhu, MV; Subhramanyam, SV, 2010)
"Medical records of 154 children with acute leukemia who received AFP with fluconazole during intensive chemotherapy were retrospectively reviewed to determine risk factors, clinical characteristics and outcome of IFI."	7.75	Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxis. ( Albayrak, M; Aral, YZ; Gursel, T; Kalkanci, A; Kaya, Z; Kocak, U, 2009)
"To assess the efficacy of 2% fluconazole subconjunctival injection as an adjunctive treatment in severe recalcitrant fungal corneal ulcer."	7.74	Efficacy of fluconazole subconjunctival injection as adjunctive therapy for severe recalcitrant fungal corneal ulcer. ( Isipradit, S, 2008)
"A cost-effectiveness analysis was performed to investigate the financial impact of using posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia."	7.74	Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia. ( Collins, CD; Ellis, JJ; Kaul, DR, 2008)
"We evaluated the impact of fluconazole prophylaxis for extremely low birth weight infants on invasive candidiasis incidence, invasive candidiasis-related mortality rates, and fluconazole susceptibility of Candida isolates."	7.74	Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species. ( Baker, CJ; Campbell, JR; Healy, CM; Zaccaria, E, 2008)
"To assess the efficacy and safety of subconjunctival fluconazole treatment as an alternative therapy for severe fungal keratitis refractory to the conventional antifungal medical treatment."	7.73	Severe fungal keratitis treated with subconjunctival fluconazole. ( Maden, A; Yilmaz, S, 2005)
"Fluconazole poly(D,L-lactic) acid (PLA) and poly(L-lactic) acid (L-PLA) implantable delivery rods were studied, in vitro and in vivo, as an alternative treatment of fungal osteomyelitis."	7.73	Biodegradable implantable fluconazole delivery rods designed for the treatment of fungal osteomyelitis: influence of gamma sterilization. ( Evora, C; Martín, AY; Sánchez, E; Soriano, I, 2006)
"Retrospective analysis of an interventional case series of five cases of culture-proven fungal endophthalmitis treated with intravitreal voriconazole was done."	7.73	Intravitreal voriconazole for drug-resistant fungal endophthalmitis: case series. ( Gopal, L; Sen, P; Sen, PR, 2006)
"Several clinical trials have demonstrated the efficacy of fluconazole as empiric antifungal therapy in cancer patients with fever and neutropenia."	7.73	Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia. ( Bates, DW; Kumar, RN; Peterson, JF; Seger, DL; Yu, DT, 2006)
"(1) To determine the pharmacokinetics of sequential intravenous and enteral fluconazole in the serum of surgical intensive care unit (ICU) patients with deep mycoses."	7.71	Pharmacokinetics of sequential intravenous and enteral fluconazole in critically ill surgical patients with invasive mycoses and compromised gastro-intestinal function. ( Bruining, HA; Buijk, SL; Gyssens, IC; Mouton, JW; Touw, DJ; Verbrugh, HA, 2001)
"To describe the association between fluconazole and reversible alopecia."	7.69	Alopecia associated with fluconazole therapy. ( Bamberger, DM; Chapman, SW; Hamill, R; Johnson, PC; Kauffman, CA; McKinsey, DS; Pappas, PG; Perfect, J; Sharkey, PK; Sobel, JD, 1995)
"The bis triazole agent fluconazole is used widely in the treatment of superficial and deep mycoses."	7.69	Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. ( Debruyne, D, 1997)
"We report on four cases of aspergillosis which developed during therapy with fluconazole in patients who were immunosuppressed or granulocytopenic."	7.68	Fluconazole in patients at risk from invasive aspergillosis. ( Kappe, R; Osterziel, KJ; Rüchel, R; Siehl, S, 1993)
" Itraconazole was superior to fluconazole in candidosis, cryptococcosis, sporotrichosis and aspergillosis, and to amphotericin B and to flucytosine in candidosis, cryptococcosis and aspergillosis."	7.68	In vitro antifungal spectrum of itraconazole and treatment of systemic mycoses with old and new antimycotic agents. ( Van Cutsem, J, 1992)
"The efficacy and safety of fluconazole, a new triazole antifungal agent, was evaluated in 24 patients with neutropenia due to cytotoxic anticancer chemotherapy with polyfactorial immunodepression."	7.68	Fluconazole in the treatment of mycotic oropharyngeal stomatitis and esophagitis in neutropenic cancer patients. ( Blahova, M; Fuchsberger, P; Hornikova, M; Koza, I; Krcméry, V; Mardiak, J; Migom, C; Savko, V; Spanik, S; Sufliarsky, J, 1991)
"Efficacies of fluconazole, a new triazole antifungal agent, were evaluated in 11 cases of systemic mycoses (1 case each of candiduria, pulmonary cryptococcosis, pulmonary aspergillosis, pulmonary penicilliosis and suspected fungal pulmonary infection, and 3 cases each of candidemia and Candida endophthalmitis)."	7.67	[Fluconazole treatment of systemic mycoses]. ( Ebe, T; Hamamoto, T; Hibiya, I; Inagaki, M; Isonuma, H; Kohara, T; Matsumura, M; Mori, T; Takahashi, M; Watanabe, K, 1989)
"Fluconazole proved effective in treating fungal peritonitis caused by Trichosporon cutaneum."	7.67	Fluconazole therapy for fungal peritonitis in continuous ambulatory peritoneal dialysis (CAPD): a case report. ( Ahlmén, J; Carlsson, L; Edebo, L; Eriksson, C; Torgersen, AK, 1989)
" In this study, the authors observed the clinical efficacy of Sophora gel combined with Fluconazole capsules in treating mycotic vaginitis, in order to seek an effective method for treating mycotic vaginitis."	6.80	[Clinical observation on treatment of mycotic vaginitis with Sophora gel combined with Fluconazole capsules]. ( Cui, L; Ma, CF; Wang, HX; Wang, NM, 2015)
"Fungal infections are a major cause of morbidity and mortality in patients undergoing induction chemotherapy for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS)."	6.71	Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. ( Beran, M; Cortes, J; Estey, E; Giles, F; Kantarjian, H; Koller, C; Kontoyiannis, D; Mattiuzzi, GN; Munsell, M; Raad, I; Shen, Y, 2003)
"Oral fluconazole was used as initial therapy in all patients, which was followed by catheter removal if peritonitis failed to improve."	6.67	Treatment of fungal peritonitis complicating continuous ambulatory peritoneal dialysis with oral fluconazole: a series of 21 patients. ( Chan, CY; Chan, TM; Cheng, IK; Cheng, SW; Lo, CY; Lo, WK, 1994)
"Fluconazole (FLU) is a new antifungal agent that has been used successfully to treat Candida infections and has modest activity against aspergillosis in animal models."	6.67	Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. ( Anaissie, EJ; Bodey, GP; Elting, LS; Estey, E; Kantarjian, H; O'Brien, S, 1994)
"Fluconazole (FLCZ) is an antifungal agent of triazole class developed by Pfizer, Inc."	6.67	[A clinical study of fluconazole-granules and -injectable in pediatric patients with deep-seated mycoses]. ( Fujii, R; Hatae, Y; Ishikawa, Y; Kobayashi, M; Matsumoto, S; Sakiyama, Y; Sunakawa, K; Takase, A; Takeda, T; Yokota, T, 1993)
"Fluconazole was given empirically, but had no effect."	6.45	Fluconazole-resistant Kodamaea ohmeri fungemia associated with cellulitis: case report and review of the literature. ( Hou, SJ; Lee, SY; Lu, JJ; Peng, MY; Sun, JR; Yang, BH, 2009)
"Fluconazole is a triazole antifungal agent which is now an established part of therapy in patients with immune deficiencies."	6.39	Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. ( Barradell, LB; Goa, KL, 1995)
"Fluconazole is a bis-triazole antifungal drug with novel pharmacokinetic properties (metabolic stability, relatively high water solubility) which contribute to its therapeutic activity."	6.38	Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. ( Clissold, SP; Grant, SM, 1990)
"Fluconazole prophylaxis was accompanied by a significant decrease in both the rate and number of days of bacterial infections as well as co-infections."	5.40	Fluconazole prophylaxis is associated with a decreased rate of coagulase-negative Staphylococcal infections in a subset of extremely low birth weight neonates. ( Abou Jaoude, R; DeBari, VA; Lamacchia, M; McClure, D; Morel, C; Zauk, A, 2014)
"Fluconazole prophylaxis was administered following 44 cycles (fluconazole group) and not given in 32 cycles (control group)."	5.36	Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high-dose cytarabine consolidations and thus do not require prophylaxis. ( Deremer, D; Dobbins, R; Eisa, N; El-Geneidy, M; Hall, P; Jillella, A; Lewis, G; Ustun, C, 2010)
"Treatment with fluconazole alone has an effect comparable to intraperitoneal (IP) amphotericin B alone or IP amphotericin B combined with oral or intravenous fluconazole."	5.32	Fungal peritonitis in peritoneal dialysis patients: effect of fluconazole treatment and use of the twin-bag disconnect system. ( Chen, CM; Ho, MW; Wang, JH; Yu, WL, 2004)
"To compare the efficacy of caspofungin vs fluconazole prophylaxis against proven or probable invasive fungal disease and invasive aspergillosis during neutropenia following acute myeloid leukemia chemotherapy."	5.30	Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial. ( Alexander, S; Callahan, C; Chen, L; Dang, H; Dvorak, CC; Esbenshade, AJ; Fisher, BT; Nieder, M; Sung, L; Villaluna, D; Wiley, JM; Wingard, JR; Zaoutis, T; Zerr, D, 2019)
"The results of a pharmacoeconomic study of the cost-effectiveness of posaconazole versus fluconazole in preventing invasive fungal infections (IFIs) in patients with graft-versus-host disease (GVHD) are reported."	5.16	Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease. ( Langston, AA; O'Sullivan, AK; Pandya, A; Papadopoulos, G; Perfect, JR; Thompson, D; Weinstein, MC, 2012)
"To test the hypothesis that fluconazole plus standard care is superior to the standard care for diabetic foot wounds infected with deep-seated fungal infections."	5.16	Targeted treatment of invasive fungal infections accelerates healing of foot wounds in patients with Type 2 diabetes. ( Bal, A; Chellan, G; Dinesh, KR; Jayakumar, RV; Kumar, H; Mangalanandan, TS; Neethu, K; Shashikala, S; Sundaram, KR; Varma, AK; Varma, N, 2012)
" The authors conducted the first prospective, randomised controlled trial of nystatin compared with fluconazole for the prevention of fungal colonisation and invasive fungal infection in very low birth weight (VLBW) neonates."	5.15	Randomised controlled trial of prophylactic fluconazole versus nystatin for the prevention of fungal colonisation and invasive fungal infection in very low birth weight infants. ( Akar, M; Aydemir, C; Dilmen, U; Dizdar, EA; Erdeve, O; Oguz, SS; Sarikabadayi, YU; Saygan, S, 2011)
"We audited the effect of co-prescription of daily oral fluconazole with antibiotics in the Pan Thames centres on fungal peritonitis."	5.15	Does antifungal prophylaxis with daily oral fluconazole reduce the risk of fungal peritonitis in peritoneal dialysis patients? The Pan Thames Renal Audit. ( Davenport, A; Wellsted, D, 2011)
" Cefpirome was administered as prophylaxis against bacterial infection, and meropenem+minocycline as an empiric window therapy for febrile neutropenia."	5.14	[Comparison of micafungin and fosfluconazole as prophylaxis for invasive fungal infection during neutropenia in children undergoing chemotherapy and hematopoietic stem cell transplantation]. ( Higuchi, B; Hirano, S; Inoue, M; Ishihara, T; Kawa, K; Kondo, O; Kouroki, M; Koyama, M; Sakata, A; Sakata, N; Sawada, A; Takeshita, Y; Yasui, M; Yoshioka, A, 2009)
"The objective of this study was to assess the costs and effectiveness (avoided invasive fungal infections - IFIs; overall mortality) of prophylaxis with posaconazole 200 mg per os TID and standard azoles (fluconazole 400 mg per os OD, itraconazole 200 mg per os BID) in neutropenic patients with acute myelogenous leukaemia or myelodysplastic syndromes."	5.14	[Economic evaluation of posaconazole in prophylaxis of invasive fungal infections in Italian neutropenic patients with acute myeloid leukaemia or myelodysplastic syndrome]. ( Lazzaro, C, 2010)
" The patient in this case responded to isavuconazole treatment for breakthrough infection due to B raffinosifermentans that was cultured from pleural fluid while on posaconazole prophylaxis post-bilateral lung transplantation for cystic fibrosis."	5.12	Pulmonary infection secondary to Blastobotrys raffinosifermentans in a cystic fibrosis patient: Review of the literature. ( Al-Obaidi, M; Badali, H; Cañete-Gibas, C; Patterson, HP; Wiederhold, NP, 2021)
"5 mg/kg twice daily; N=248) with fluconazole oral solution or capsules (400 mg daily; N=246) in 494 patients with anticipated profound neutropenia (i."	5.12	An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. ( Andreesen, R; Bertz, H; Bodenstein, H; Boewer, C; Cornely, O; Dölken, G; Glasmacher, A; Hänel, M; Junghanss, C; Pasold, R; Ullmann, AJ; Wandt, H; Wedding, U; Wolf, HH, 2006)
"In an international, randomized, double-blind trial, we compared oral posaconazole with oral fluconazole for prophylaxis against invasive fungal infections in patients with graft-versus-host disease (GVHD) who were receiving immunosuppressive therapy."	5.12	Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. ( Boparai, N; Chandrasekar, P; Durrant, S; Greinix, H; Langston, A; Lipton, JH; Morais de Azevedo, W; Patino, H; Pedicone, L; Reddy, V; Tarantolo, SR; Ullmann, AJ; Vesole, DH, 2007)
"In patients undergoing chemotherapy for acute myelogenous leukemia or the myelodysplastic syndrome, posaconazole prevented invasive fungal infections more effectively than did either fluconazole or itraconazole and improved overall survival."	5.12	Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. ( Angulo-Gonzalez, D; Cornely, OA; Goh, YT; Hardalo, C; Helfgott, D; Holowiecki, J; Maertens, J; Perfect, J; Petrini, M; Stockelberg, D; Suresh, R; Ullmann, AJ; Walsh, TJ; Winston, DJ, 2007)
"We performed a randomized, controlled study comparing the prophylactic effects of capsule forms of fluconazole (n = 110) and itraconazole (n = 108) in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) during and after chemotherapy."	5.12	The prophylactic effect of itraconazole capsules and fluconazole capsules for systemic fungal infections in patients with acute myeloid leukemia and myelodysplastic syndromes: a Japanese multicenter randomized, controlled study. ( Aoyama, Y; Ito, Y; Kanamaru, A; Kiguchi, T; Masaoka, T; Matsuda, M; Matsuura, Y; Mugitani, A; Ohyashiki, K; Sakamoto, E; Takeuchi, M; Tamura, K; Urabe, A; Wakita, H; Yoshida, I, 2007)
"We hypothesized that chemoprophylaxis with the echinocandin micafungin would be an effective agent for antifungal prophylaxis during neutropenia in patients undergoing hematopoietic stem cell transplantation (HSCT)."	5.11	Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. ( Bunin, N; Hiemenz, JW; Lee, JM; Lipton, JH; Miller, CB; Ratanatharathorn, V; Satoi, Y; Stepan, DE; van Burik, JA; Vesole, DH; Wall, DA; Walsh, TJ, 2004)
" Fluconazole clearance was dependent on creatinine clearance, and volume of distribution was dependent on body weight and age."	5.10	Enteral fluconazole population pharmacokinetics in patients in the surgical intensive care unit. ( Hendrix, CW; Lipsett, PA; Pelz, RK; Rajagopalan, P; Rinaldi, MG; Swoboda, SM, 2003)
" Patients receiving fluconazole had higher serum cyclosporine levels and more adverse neurologic events (headaches, tremors, or seizures in 13 fluconazole recipients compared with 3 placebo recipients; P = 0."	5.09	Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. ( Busuttil, RW; Pakrasi, A; Winston, DJ, 1999)
"A total of 317 neutropenic patients (<500 cells/mm3) with persistent or recrudescent fever despite 4 or more days of antibacterial therapy were randomly assigned to receive either fluconazole (400 mg intravenously once daily) or amphotericin B (0."	5.09	A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. ( Hathorn, JW; Schiller, GJ; Schuster, MG; Territo, MC; Winston, DJ, 2000)
"A pilot exploratory study was undertaken to collect preliminary information relating to safety and overall outcome in using intravenous fluconazole (FLUC) for managing antibiotic resistant neutropenic fever (ARNF), with the objective of assessing feasibility of performing a larger prospective controlled study."	5.08	Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever--preliminary observations from a pilot, exploratory study. ( Baillie, F; Clink, H; Ellis, ME; Ernst, P; Greer, W; Halim, MA; Kalin, M; Spence, D, 1995)
"Amphotericin B, despite its intrinsic servere toxicity, is the most commonly used empirical antifungal therapy in cancer patients with unexplained fever not responding to empirical antibacterial therapy."	5.08	Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. ( Caselli, D; Castagnola, E; Congiu, M; Fanci, R; Garaventa, A; Giacchino, M; Menichetti, F; Moroni, C; Rossi, MR; Van Lint, MT; Viscoli, C, 1996)
"The purpose of this prospective, open-label, noncomparative, multicentre study was to evaluate the efficacy and safety of fluconazole in the treatment of hospitalised patients with mycoses."	5.08	Large-scale multicentre study of fluconazole in the treatment of hospitalised patients with fungal infections. Multicentre European Study Group. ( Troke, PF, 1997)
"We randomly assigned 106 patients with absolute neutropenia (< or = 500 cells microL) and persistent fever of undetermined origin (> 38 degrees C) despite 1 week of broad-spectrum antibiotic therapy to receive either fluconazole 400 mg orally daily or amphotericin B 0."	5.08	A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. ( Aziz, Z; Khan, S; Malik, IA; Moid, I; Suleman, M, 1998)
"The efficacy and safety of oral fluconazole versus a polyene regimen in preventing mycoses in neutropenic patients was compared."	5.07	Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients. ( Burnie, J; Clink, H; Ellis, ME; Ernst, P; Greer, W; Halim, MA; Hussain Qadri, SM; Kalin, M; Padmos, A; Spence, D, 1994)
"To compare the efficacy and tolerability of fluconazole and oral amphotericin B in preventing fungal infection in neutropenic patients with acute leukemia."	5.07	Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. ( Barbui, T; Bucaneve, G; Carotenuto, M; D'Antonio, D; Del Favero, A; Fasola, G; Liso, V; Mandelli, F; Martino, P; Menichetti, F; Micozzi, A; Nosari, AM; Ricci, P, 1994)
"An open, randomized study was performed at 18 European centres to compare the efficacy, safety and tolerance of oral fluconazole with oral polyenes for the prophylaxis of fungal colonization and infection in adults at high risk of developing neutropenia."	5.07	Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group. ( Brammer, KW; Ehninger, G; Mufti, GJ; Philpott-Howard, JN; Wade, JJ, 1993)
"Prophylactic fluconazole prevents colonization and superficial infections by Candida species other than Candida krusei in patients undergoing chemotherapy for acute leukemia and is well tolerated."	5.07	Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. ( Buell, DN; Chandrasekar, PH; Goodman, JL; Ho, WG; Horowitz, H; Islam, MZ; Lazarus, HM; Rosenfeld, CS; Shadduck, RK; Silber, JL; Winston, DJ, 1993)
"The recently developed antifungal agents itraconazole and fluconazole have been evaluated for primary and maintenance therapy for mycoses in patients with acquired immune deficiency syndrome (AIDS) in comparative and non-comparative trials."	5.07	Opportunistic fungal infections in patients with acquired immune deficiency syndrome. ( Viviani, MA, 1992)
"Eighty-eight immunocompetent patients with deep mycoses from eight countries were evaluated with the same protocol for efficacy of fluconazole monotherapy."	5.07	A Pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. Pan-American Study Group. ( Arathoon, EG; Borelli, D; Bran, JL; Castro, LG; Diaz, M; Franco, L; Montero-Gei, F; Negroni, R; Restrepo, A; Sampaio, SA, 1992)
"Forty patients with acute leukemia (age 16-71 years, 13 females, 27 males) with induced neutropenia due to chemotherapy received either 50 mg fluconazole or 800 mg amphotericin B per day orally as prophylaxis against fungal infection."	5.06	[Comparison of oral fluconazole and amphotericin B prophylaxis against fungal infections in the neutropenic phase of patients treated with antileukemic agents]. ( Finke, R, 1990)
"To compare the benefits and harms of voriconazole with those of amphotericin B and fluconazole when used for prevention or treatment of invasive fungal infections in cancer patients with neutropenia."	4.90	Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia. ( Dalbøge, CS; Gøtzsche, PC; Johansen, HK; Jørgensen, KJ, 2014)
"To compare the effect of fluconazole and amphotericin B on morbidity and mortality in patients with cancer complicated by neutropenia."	4.90	Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients. ( Gøtzsche, PC; Johansen, HK, 2014)
" Terms such as micafungin, aspergillosis, zygomycosis, invasive fungal infections, emerging fungal infections, antifungal treatment or therapy, antifungal prophylaxis, empiric or pre-emptive therapy were crossed."	4.85	[Future role of micafungin in the treatment of invasive mycoses caused by filamentous fungi]. ( Salavert-Lletí, M; Zaragoza-Crespo, R, 2009)
"The oral agents for deep-seated mycoses that can be used in Japan are amphotericin B, flucytosine, fluconazole, itraconazole, and voriconazole."	4.84	[Oral antifungal agents]. ( Maesaki, S; Tarumoto, N, 2008)
"To compare the benefits and harms of voriconazole with those of amphotericin B and fluconazole when used for prevention or treatment of invasive fungal infections in cancer patients with neutropenia."	4.83	Voriconazole versus amphotericin B in cancer patients with neutropenia. ( Gøtzsche, PC; Johansen, HK; Jørgensen, KJ, 2006)
"The azole antifungal voriconazole and the echinocandin caspofungin have recently become available for the treatment of invasive mycoses."	4.82	[New developments in antifungal therapy: fluconazole, itraconazole, voriconazole, caspofungin]. ( Kuijper, EJ; Kullberg, BJ; van 't Wout, JW; Verweij, PE, 2004)
"Prophylactic fluconazole administration for prevention of mycoses in SICU patients appears to successfully decrease the rate of these infections, but this strategy does not improve survival."	4.82	Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. ( Chung, K; Jackson, WL; Kollef, MH; Shorr, AF; Waterman, PE, 2005)
"To compare the effect of fluconazole and amphotericin B on morbidity and mortality in patients with cancer complicated by neutropenia."	4.81	Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients. ( Gøtzsche, PC; Johansen, HK, 2002)
"Although there are many potential changes of pharmacokinetic parameters in patients with thermal injury, obesity or septicemia, data about the actual effect on pharmacokinetics and clinical efficacy of fluconazole are very limited."	4.80	Special pharmacokinetics of fluconazole in septic, obese and burn patients. ( Penk, A; Pittrow, L, 1999)
"To compare the effect of fluconazole and amphotericin B on morbidity and mortality in patients with cancer complicated by neutropenia."	4.80	Amphotericin B vs fluconazole for controlling fungal infections in neutropenic cancer patients. ( Gotzsche, PC; Johansen, HK, 2000)
" AIDS related mycoses have decreased, and the increase of fluconazole resistant Candida albicans may be slowing because fewer severely immune depressed patients require constant fluconazole suppression."	4.80	Changing strategies for treatment of systemic mycoses. ( Graybill, JR, 2000)
"Fluconazole is compared with other agents for antifungal prophylaxis in patients with chemotherapy-induced neutropenia."	4.79	Fluconazole for antifungal prophylaxis in chemotherapy-induced neutropenia. ( Briceland, LL; Preston, SL, 1995)
"The addition of itraconazole and fluconazole to the antifungal armamentarium has resulted in less toxic, easily administered therapy for both endemic and opportunistic mycoses."	4.79	Role of azoles in antifungal therapy. ( Kauffman, CA, 1996)
"The clinical use of fluconazole in dosages > or = 800 mg/day has been reported in about 900 patients against candidemia, oropharyngeal candidiasis and cryptococcal meningitis in HIV-infected patients as well as for initial therapy of endemic mycoses."	4.79	[High-dose therapy with fluconazole > or = 800 mg/day. Review]. ( Penk, A; Pittrow, L, 1997)
"Fluconazole dosages greater than 800 mg day-1 have been reported in about 900 patients treated for candidemia, oropharyngeal candidiasis and cryptococcal meningitis in HIV-infected patients, and for initial therapy of endemic mycoses."	4.79	High-dose therapy with fluconazole > or = 800 mg day-1. ( Duswald, KH; Penk, A; Pittrow, L, 1997)
" Early studies suggest that a new acyclic nucleoside, ganciclovir, has some effect in the treatment of cytomegalovirus infections, but its precise use in patients with cancer has not been fully established."	4.78	New drugs for infections in patients with cancer. ( Hughes, WT, 1992)
"Fluconazole is a novel triazole antifungal drug chiefly used in the treatment of opportunistic mycoses in immuno-compromised patients, particularly those with the acquired immuno-deficiency syndrome (AIDS)."	4.78	Fluconazole. Review and situation among antifungal drugs in the treatment of opportunistic mycoses of human immuno-deficiency virus infections. ( Lafaix, C; Patey, ON; Vincent-Ballereau, FN, 1991)
"Based on the high clinical suspicion of fungal peritonitis, fluconazole intraperitoneal (IP) was immediately given on the first day in addition to empirical antibiotics, that is, cefazolin and gentamycin IP."	4.31	A successful management of fungal peritonitis caused by Rhodotorula glutinis in CAPD patient, coincident with onychomycosis by Penicillium sp: Case report. ( Hustrini, NM; Panggabean, SD, 2023)
"In our population of obese but otherwise healthy individuals, obesity clearly alters the pharmacokinetics of fluconazole, which puts severely obese adults, particularly if male, at risk of suboptimal exposure, for which adjusted doses are proposed."	4.12	Total bodyweight and sex both drive pharmacokinetic variability of fluconazole in obese adults. ( Brüggemann, RJ; Chen, L; Knibbe, CAJ; Krekels, EHJ; van der Linden, PD; van Dongen, EPA; van Rhee, KP; Verweij, PE; Wasmann, RE; Wiezer, MJ, 2022)
"After antifungal treatment with fluconazole, the patient's clinical symptoms gradually disappeared with the healing of gastric ulcer, which never recurred in this patient until 3 months after follow-up."	3.91	A rare case report of fungal esophagitis combined with giant gastric ulcer in an immunocompetent patient. ( Jianping, C; Juan, D; Liang, M; Liwen, Z; Yanbo, D; Yun, Z, 2019)
"To evaluate the cost-effectiveness of solid oral tablets of posaconazole versus fluconazole capsules for the prophylaxis of IFDs in allogeneic HSCT recipients with graft-versus-host disease (GVHD) in Spain."	3.88	Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. ( Aragón, B; Cámara, R; Gozalbo, I; Grau, S; Jurado, M; Sanz, J, 2018)
"Fluconazole (FLC) is the drug of choice when it comes to treat fungal infections such as invasive candidiasis in humans."	3.85	Novel alkylated azoles as potent antifungals. ( Garneau-Tsodikova, S; Garzan, A; Shrestha, SK, 2017)
"Posaconazole prophylaxis during induction chemotherapy for acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) has been shown to significantly decrease the incidence of invasive fungal disease (IFD) and increase overall survival in a trial setting, but only small real-life studies have been published."	3.83	Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes. ( Björkholm, M; Blennow, O; Cederlund, K; Dahlén, T; Kalin, M; Ljungman, P; Nordlander, A, 2016)
"Posaconazole is superior to fluconazole/itraconazole in preventing invasive fungal diseases (IFDs) in neutropenic patients."	3.83	Posaconazole vs fluconazole or itraconazole for prevention of invasive fungal diseases in patients with acute myeloid leukemia or myelodysplastic syndrome: a cost-effectiveness analysis in an Asian teaching hospital. ( Chan, TS; Gill, H; Hwang, YY; Kwong, YL; Marcella, SW, 2016)
" bantiana) associated with hypogammaglobulinemia following gastrectomy, intravenous antifungal drugs including amphotericin B and fluconazole were administered."	3.83	[Brain Abscess due to Infection with Dematiaceous Fungi Cladophialophora bantiana Associated with Hypogammaglobulinemia Following Gastrectomy: A Case Report]. ( Akiyama, T; Haga, S; Makihara, K; Morioka, T; Sayama, T; Shimogawa, T, 2016)
"Based on this laboratory study of isolates from exogenous fungal endophthalmitis, intravitreal voriconazole appears to provide the broadest spectrum of antifungal coverage and, as such, may be considered for empiric therapy of endophthalmitis caused by yeast or mold."	3.81	Exogenous fungal endophthalmitis: an analysis of isolates and susceptibilities to antifungal agents over a 20-year period (1990-2010). ( Flynn, HW; Miller, D; Silva, RA; Sridhar, J; Wykoff, CC, 2015)
"In patients undergoing induction chemotherapy for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), posaconazole has been proven more effective in the prevention of invasive fungal infection (IFI) than fluconazole or itraconazole (standard azoles) The current analysis seeks to estimate the cost effectiveness of prophylactic posaconazole compared with standard azoles in AML or MDS patients with severe chemotherapy-induced neutropenia in Sweden."	3.80	Economic evaluation of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infection in high-risk neutropenic patients in Sweden. ( Åkerborg, Ö; Björkholm, M; Höglund, M; Lundberg, J, 2014)
"In this retrospective review, we examined the incidence of FP in a cohort of 115 patients, who had received antibiotics for bacterial peritonitis and received a co-prescription of fluconazole, 50 mg/day for the duration of antibiotic therapy."	3.76	Prophylaxis against fungal peritonitis in CAPD--a single center experience with low-dose fluconazole. ( Antony, SK; Gandhe, S; Nayak, KS; Prabhu, MV; Subhramanyam, SV, 2010)
"Medical records of 154 children with acute leukemia who received AFP with fluconazole during intensive chemotherapy were retrospectively reviewed to determine risk factors, clinical characteristics and outcome of IFI."	3.75	Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxis. ( Albayrak, M; Aral, YZ; Gursel, T; Kalkanci, A; Kaya, Z; Kocak, U, 2009)
"To assess the efficacy of 2% fluconazole subconjunctival injection as an adjunctive treatment in severe recalcitrant fungal corneal ulcer."	3.74	Efficacy of fluconazole subconjunctival injection as adjunctive therapy for severe recalcitrant fungal corneal ulcer. ( Isipradit, S, 2008)
" Four patients presented nausea and vomiting as an AE, although aerosolized amphotericin B was ongoing."	3.74	Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation. ( Borro, JM; de la Torre, M; Delgado, M; Fernandez, R; Gonzalez, D; Monte, E; Pastor, A; Saura, A; Solé, A, 2008)
"A cost-effectiveness analysis was performed to investigate the financial impact of using posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia."	3.74	Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia. ( Collins, CD; Ellis, JJ; Kaul, DR, 2008)
"We evaluated the impact of fluconazole prophylaxis for extremely low birth weight infants on invasive candidiasis incidence, invasive candidiasis-related mortality rates, and fluconazole susceptibility of Candida isolates."	3.74	Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species. ( Baker, CJ; Campbell, JR; Healy, CM; Zaccaria, E, 2008)
"To assess the efficacy and safety of subconjunctival fluconazole treatment as an alternative therapy for severe fungal keratitis refractory to the conventional antifungal medical treatment."	3.73	Severe fungal keratitis treated with subconjunctival fluconazole. ( Maden, A; Yilmaz, S, 2005)
"Fluconazole poly(D,L-lactic) acid (PLA) and poly(L-lactic) acid (L-PLA) implantable delivery rods were studied, in vitro and in vivo, as an alternative treatment of fungal osteomyelitis."	3.73	Biodegradable implantable fluconazole delivery rods designed for the treatment of fungal osteomyelitis: influence of gamma sterilization. ( Evora, C; Martín, AY; Sánchez, E; Soriano, I, 2006)
"Retrospective analysis of an interventional case series of five cases of culture-proven fungal endophthalmitis treated with intravitreal voriconazole was done."	3.73	Intravitreal voriconazole for drug-resistant fungal endophthalmitis: case series. ( Gopal, L; Sen, P; Sen, PR, 2006)
"Several clinical trials have demonstrated the efficacy of fluconazole as empiric antifungal therapy in cancer patients with fever and neutropenia."	3.73	Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia. ( Bates, DW; Kumar, RN; Peterson, JF; Seger, DL; Yu, DT, 2006)
"Data from an 8-year period for 46 patients with severe acute pancreatitis and infected pancreatic necrosis were analyzed to determine the incidence of fungal infection, to identify risk factors for the development of fungal infection, and to assess the use of early fluconazole treatment."	3.72	Fungal infections in patients with severe acute pancreatitis and the use of prophylactic therapy. ( Blot, S; Colardyn, F; De Waele, JJ; Vogelaers, D, 2003)
"(1) To determine the pharmacokinetics of sequential intravenous and enteral fluconazole in the serum of surgical intensive care unit (ICU) patients with deep mycoses."	3.71	Pharmacokinetics of sequential intravenous and enteral fluconazole in critically ill surgical patients with invasive mycoses and compromised gastro-intestinal function. ( Bruining, HA; Buijk, SL; Gyssens, IC; Mouton, JW; Touw, DJ; Verbrugh, HA, 2001)
"We describe a case of Acremonium falciforme fungemia under treatment of fluconazole."	3.71	Case Report. Acremonium falciforme fungemia in a patient with acute leukaemia. ( Erdem, F; Nedret Koç, A; Patiroğlu, T, 2002)
" We describe the unanticipated problems we encountered in collecting data for a meta-analysis comparing a new antifungal agent, fluconazole, with amphotericin B in patients with cancer complicated by neutropenia."	3.70	Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. ( Gotzsche, PC; Johansen, HK, 1999)
"To describe the association between fluconazole and reversible alopecia."	3.69	Alopecia associated with fluconazole therapy. ( Bamberger, DM; Chapman, SW; Hamill, R; Johnson, PC; Kauffman, CA; McKinsey, DS; Pappas, PG; Perfect, J; Sharkey, PK; Sobel, JD, 1995)
" One patient had developed a chronic systemic candidiasis during consolidation chemotherapy and received prophylactic oral or iv fluconazole (200 mg daily) throughout BMT."	3.69	Successful bone marrow transplantation in patients with previous invasive fungal infections: report of four cases. ( Altés, A; Brunet, S; Domingo-Albós, A; Martínez, C; Martino, R; Nomdedéu, J; Sureda, A, 1994)
"Two patients who developed fungal peritonitis after receiving continuous ambulatory peritoneal dialysis (CAPD) for various periods were successfully treated with intracatheter retention of amphotericin B 1-2 mg and oral flucytosine or fluconazole 50 mg b."	3.69	Successful treatment of fungal peritonitis with intracatheter antifungal retention. ( Chiang, SS; Hseih, SJ; Lee, SH; Shen, HM, 1995)
"To evaluate the efficacy and safety of oral fluconazole treatment for the prevention of systemic fungal diseases related to the acquired immunodeficiency syndrome."	3.69	Fluconazole as prophylaxis against fungal infection in patients with advanced HIV infection. ( Chiodo, F; Coronado, OV; Manfredi, R; Mastroianni, A, 1997)
"Two children with fungal urinary tract infections (UTI) were treated with fluconazole."	3.69	Fluconazole for treatment of fungal infections of the urinary tract in children. ( Mirza, I; Zia-ul-Miraj, M, 1997)
"The bis triazole agent fluconazole is used widely in the treatment of superficial and deep mycoses."	3.69	Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. ( Debruyne, D, 1997)
" Other topics included an outline of the World Health Organization's (WHO) stepped-care strategy for pain management, a discussion on the benefits of fluconazole prophylaxis in treating opportunistic infections, and the need to confirm self-reported HIV infection to avoid the problem of some people attempting to gain a secondary benefit by claiming to be HIV-positive."	3.69	First women's HIV conference hears go-for-broke antiretroviral strategy. ( Mascolini, M, 1995)
"Efficacy of fluconazole (FLCZ), an anti-fungal agent of triazole derivatives, was evaluated in patients with systemic mycoses and suspected mycoses associated with hematologic malignancies including leukemia, myelodysplastic syndrome and malignant lymphoma."	3.68	[Efficacy of fluconazole on systemic mycosis associated with hematologic malignancies and a study on diagnostic value of plasma beta-D-glucan levels]. ( Hirakawa, K; Horiike, S; Kashima, K; Kuzuyama, Y; Misawa, S; Nakai, H; Seryu, T; Takashima, T; Taniwaki, M; Tsuda, S, 1993)
"We report on four cases of aspergillosis which developed during therapy with fluconazole in patients who were immunosuppressed or granulocytopenic."	3.68	Fluconazole in patients at risk from invasive aspergillosis. ( Kappe, R; Osterziel, KJ; Rüchel, R; Siehl, S, 1993)
"Twelve patients receiving therapy with an azole agent (ketoconazole, itraconazole, and/or fluconazole) for systemic mycoses experienced drug interactions with rifampin, phenytoin, and/or carbamazepine resulting in substantial decreases in azole concentrations in serum."	3.68	Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. ( Denning, DW; Graybill, JR; Hanson, LH; Pappagianis, D; Rinaldi, MG; Sharkey, PK; Stevens, DA; Tucker, RM, 1992)
" Itraconazole was superior to fluconazole in candidosis, cryptococcosis, sporotrichosis and aspergillosis, and to amphotericin B and to flucytosine in candidosis, cryptococcosis and aspergillosis."	3.68	In vitro antifungal spectrum of itraconazole and treatment of systemic mycoses with old and new antimycotic agents. ( Van Cutsem, J, 1992)
"The efficacy and safety of fluconazole, a new triazole antifungal agent, was evaluated in 24 patients with neutropenia due to cytotoxic anticancer chemotherapy with polyfactorial immunodepression."	3.68	Fluconazole in the treatment of mycotic oropharyngeal stomatitis and esophagitis in neutropenic cancer patients. ( Blahova, M; Fuchsberger, P; Hornikova, M; Koza, I; Krcméry, V; Mardiak, J; Migom, C; Savko, V; Spanik, S; Sufliarsky, J, 1991)
"Fluconazole, a novel triazole antifungal drug, holds promise as a significant advance in the management of human fungal diseases."	3.68	Fluconazole vs amphotericin B: "in vitro" comparative evaluation of the minimal inhibitory concentration (MIC) against yeasts isolated from AIDS patients. ( Cavanna, C; Gramegna, G; Lombardi, G; Michelone, G, 1990)
"Clinical evaluation of fluconazole was performed on 12 cases of mycotic infections (7 cases of Candida esophagitis; one each case of cryptococcal meningitis with AIDS, Candida tropicalis fungemia and disseminated cryptococcosis in kidney transplant patient; 2 cases of Candida pneumonia)."	3.67	[Clinical evaluation of fluconazole]. ( Goto, H; Goto, M; Mori, H; Nakata, H; Oka, S; Shimada, K; Tokitsu, M, 1989)
"Efficacies of fluconazole, a new triazole antifungal agent, were evaluated in 11 cases of systemic mycoses (1 case each of candiduria, pulmonary cryptococcosis, pulmonary aspergillosis, pulmonary penicilliosis and suspected fungal pulmonary infection, and 3 cases each of candidemia and Candida endophthalmitis)."	3.67	[Fluconazole treatment of systemic mycoses]. ( Ebe, T; Hamamoto, T; Hibiya, I; Inagaki, M; Isonuma, H; Kohara, T; Matsumura, M; Mori, T; Takahashi, M; Watanabe, K, 1989)
"Fluconazole proved effective in treating fungal peritonitis caused by Trichosporon cutaneum."	3.67	Fluconazole therapy for fungal peritonitis in continuous ambulatory peritoneal dialysis (CAPD): a case report. ( Ahlmén, J; Carlsson, L; Edebo, L; Eriksson, C; Torgersen, AK, 1989)
"Combination pairs of 5-fluorocytosine (5-FC) + itraconazole (Itra), 5-FC + fluconazole (Fluc), and amphotericin B (Amph B) + Itra were administered to mice with experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis with a variety of combination ratios."	3.67	Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice. ( Polak, A, 1987)
"Patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and allogeneic hematopoietic cell transplant recipients were randomly assigned to receive caspofungin empirically (arm A) or preemptively (arm B), while receiving fluconazole 400 mg daily prophylactically."	3.30	Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer. ( Ameye, L; Aoun, M; Barnes, R; Baron, F; Bertz, H; Blijlevens, N; Bochud, PY; Chantepie, S; Cheung, KJ; Coiteux, V; Cordonnier, C; Donnelly, JP; Drgona, L; Heinz, WJ; Hepler, DA; Lamoth, F; Llorente, CC; Lodewyck, T; Loeffler, J; Maertens, J; Marchetti, O; Meert, L; Paesmans, M; Ráčil, Z; Robin, C; Schaefer-Prokop, C; Schwarzinger, M; Selleslag, D; Turlure, P; Vandercam, B; Verweij, P, 2023)
" Our research indicated that the application of fluconazole did not result in intolerable adverse reactions in patients."	3.01	The efficacy and safety of fluconazole in preventing invasive fungal infection in very low birth weight infants: a systematic review and meta-analysis. ( Xie, J; Zeng, J; Zheng, S, 2023)
"Although invasive fungal infections (IFIs) contribute to substantial morbidity and mortality in liver transplant recipients, only a few randomized studies analyzed the results of antifungal prophylaxis with echinocandins."	2.94	A Multicenter, Randomized, Open-Label Study to Compare Micafungin with Fluconazole in the Prophylaxis of Invasive Fungal Infections in Living-Donor Liver Transplant Recipients. ( Choi, DL; Joh, JW; Kang, WH; Kim, JD; Kim, JM; Kim, MS; Kwon, CHD; Lee, KW; Lee, SG; Song, GW; Suh, KS; Yi, NJ, 2020)
"The prevalence of fungal secondary infections among COVID-19 patients and efficacy of antifungal therapy used in such patients is still unknown."	2.82	Antifungal therapy in the management of fungal secondary infections in COVID-19 patients: A systematic review and meta-analysis. ( Kumar, TMP; Pathakamuri, N; Ramaswamy, S; Ramesh, M; Sah, SK; Shariff, A; Srikanth, MS; Undela, K, 2022)
" In this study, the authors observed the clinical efficacy of Sophora gel combined with Fluconazole capsules in treating mycotic vaginitis, in order to seek an effective method for treating mycotic vaginitis."	2.80	[Clinical observation on treatment of mycotic vaginitis with Sophora gel combined with Fluconazole capsules]. ( Cui, L; Ma, CF; Wang, HX; Wang, NM, 2015)
"Posaconazole is a broad-spectrum triazole antifungal drug with efficacy in prevention of IFI; however, it has not been previously studied as prophylaxis in a Chinese population."	2.78	Posaconazole vs. fluconazole as invasive fungal infection prophylaxis in China: a multicenter, randomized, open-label study. ( Chen, FP; Chen, XQ; Hu, JD; Huang, XJ; Jin, J; Li, Y; Liang, YM; Liu, T; Shen, Y; Shen, ZX; Wang, JX; Wang, SJ; Wu, DP; Yu, K; Yu, L, 2013)
"Micafungin treatment did not result in increasing adverse effects and had a safe profile as fluconazole in neutropenic patients."	2.73	Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation. ( Asakura, S; Fujii, N; Hara, M; Hiramatsu, Y; Ikeda, K; Maeda, Y; Matsuo, K; Matsuoka, KI; Miyata, A; Nawa, Y; Saito, T; Shinagawa, K; Sunami, K; Tabayashi, T; Tanimoto, M; Yano, T, 2008)
" Pulmonary mechanics were measured before and after each dose of inhaled ABLC; adverse events (AEs) and the development of IFI were also monitored."	2.72	Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. ( Addison, RM; Alexander, BD; Alspaugh, JA; Chao, NJ; Dodds Ashley, ES; Perfect, JR, 2006)
"Fungal infections are a major cause of morbidity and mortality in patients undergoing induction chemotherapy for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS)."	2.71	Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. ( Beran, M; Cortes, J; Estey, E; Giles, F; Kantarjian, H; Koller, C; Kontoyiannis, D; Mattiuzzi, GN; Munsell, M; Raad, I; Shen, Y, 2003)
"Prophylactic dosage of antifungal agents (garlicin or low dosage fluconazole) can reduce the incidence of fungal infection in patients with SAP."	2.71	Prevention and therapy of fungal infection in severe acute pancreatitis: A prospective clinical study. ( Ai, ZL; Chen, JW; He, YM; Jiang, CQ; Lei, DX; Liu, ZS; Lv, XS; Qian, Q; Sun, Q; Yuan, YF, 2003)
" Pharmacokinetic profiles for micafungin on days 1 and 7 were similar."	2.71	Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. ( Buell, D; Cagnoni, P; Chao, N; Devine, S; Facklam, D; Hiemenz, J; Keirns, J; Lau, W; Simpson, D, 2005)
"Fluconazole was given intravenously by infusion."	2.71	Fungal chemoprophylaxis with fluconazole in preterm infants. ( Brussi, MM; Díez Fernández, R; Farfán Sedano, FJ; Martínez Sesmero, JM; Molina García, T; Montojo Guillén, C; Sánchez-Rubio Ferrández, J, 2005)
"Oral itraconazole solution has adequate bioavailability in liver transplant recipients for effective antifungal prophylaxis."	2.70	Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. ( Busuttil, RW; Winston, DJ, 2002)
"If fluconazole was administered orally, blood samples were drawn 2, 8, and 24 hr after ingestion of the drug."	2.70	Serum levels of fluconazole in patients after cytotoxic chemotherapy for hematological malignancy. ( Chiba, S; Hirai, H; Hirate, J; Kami, M; Kanda, Y; Kojima, N; Mori, S; Moriya, A; Saito, T; Sawada, Y; Yuji, K, 2001)
"Invasive fungal infections have increasingly become a matter of concern with regard to patients receiving intensive myelosuppressive therapy for hematologic malignancies."	2.69	Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group. ( Behre, G; Büchner, T; Eimermacher, H; Grote-Metke, A; Hiddemann, W; Kerkhoff, A; Kern, W; Kubica, U; Rudolf, T; Wörmann, B, 1998)
"We compared the efficacy of a 400-mg once-weekly dosage versus a 200-mg daily dosage of fluconazole for the prevention of deep fungal infections in a multicenter, randomized, double-blind trial of 636 human immunodeficiency virus-infected patients to determine if a less intensive fluconazole regimen could prevent these serious but relatively infrequent complications of AIDS."	2.69	Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. ( Bozzette, SA; Cheeseman, SH; Dubé, MP; Dunne, MW; Forthal, DN; Havlir, DV; Kemper, CA; Kumar, PN; MacGregor, RR; McCutchan, JA; Nightingale, SD; Parenti, DM; Sattler, FR; Sepkowitz, KA; Torriani, FJ; White, AC; Witt, MD; Zelasky, MT, 1998)
" Itraconazole has a broader spectrum of activity but the capsules give erratic bioavailability in neutropenic patients."	2.69	A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group. ( Morgenstern, GR; Prentice, AG; Prentice, HG; Ropner, JE; Schey, SA; Warnock, DW, 1999)
"Although fungal urinary tract infections are an increasing nosocomial problem, the significance of funguria is still not clear."	2.69	Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. ( Dismukes, WE; Gallis, HA; Karchmer, AW; Kauffman, CA; Lee, JY; Mangi, R; McKinsey, DS; Mosher, A; Sharkey, PK; Sobel, JD; Sugar, AM; Vazquez, JA; Wise, GJ, 2000)
"Fluconazole was discontinued when a neutrophil count above 1."	2.69	Antifungal prophylaxis with low doses fluconazole in patients with hematological malignancies. ( Goranov, S; Grudeva-Popova, J; Spasov, E; Vakrilov, V, 1999)
"Amphotericin B was significantly more toxic than Fluconazole especially in related allogeneic transplantation where 19% of patients developed toxicity vs 0% of Fluconazole recipients (p < 0."	2.69	Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group. ( Bolwell, B; Collins, R; Dummer, S; Ericson, S; Fay, J; Freytes, CO; Goodman, SA; Greer, J; Herzig, RH; LeMaistre, F; Lynch, J; Pineiro, L; Pohlman, B; Stein, R; Stevens, D; Wolff, SN, 2000)
"Fluconazole prophylaxis was given to 12 patients for a mean of 21."	2.69	Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial. ( Huijgens, PC; Simoons-Smit, AM; Timmers, GJ; Touw, D; van Loenen, AC; Zweegman, S, 2000)
"Fungal infections are a major problem in patients with hematologic malignancy."	2.68	Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. ( Schaffner, A; Schaffner, M, 1995)
"Fluconazole was found to be effective for preventing systemic fungal infections in neutropenic patients with cancer."	2.68	Prophylactic use of fluconazole in neutropenic cancer patients. ( Haznedar, R; Senol, E; Yamaç, K, 1995)
" Adverse events, plasma levels, and clinical response were examined."	2.68	Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. ( Anaissie, EJ; Bodey, GP; Bosso, J; Huls, C; Karl, C; Kontoyiannis, DP; Prince, RA; Vartivarian, SE, 1995)
"Fluconazole was also effective in preventing esophageal candidiasis (adjusted relative hazard, 5."	2.68	A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. ( Carey, J; Eyster, ME; Feinberg, J; Finkelstein, D; Frame, P; He, W; Koletar, SL; Powderly, WG; van der Horst, C; Waskin, H, 1995)
"Fluconazole was well tolerated and no early or late toxicity was observed."	2.68	[Can the prophylactic treatment of mycotic mucositis improve the time of performing radiotherapy in head and neck tumors?]. ( Coghetto, F; Ferrarese, F; Gava, A; Marazzato, G; Tonetto, V; Zorat, PL, 1996)
" The dosage and therapeutic duration were as follows: Flu 200-400 mg daily for 1-8 weeks in 34 patients with fungal infection and 150 mg as a single dose in 30 patients with fungal vaginitis; Keto 400 mg daily for 1-8 weeks in 30 patients with fungal diseases and for 5 days in 30 patients with fungal vaginitis."	2.68	[Fluconazole versus ketoconazole in systemic fungal infection: a double-blind randomized study]. ( Liang, D; Lu, Y; Zhang, H, 1997)
"Two different flucytosine (5-FC) treatment regimens, one by itself and the other in combination with fluconazole (FLCZ) were compared in chemotherapy against mycotic infections in 60 patients with hematological diseases."	2.67	[A comparative clinical study on flucytosine alone and in combination with fluconazole in hematological malignancies: a multicenter study using the envelope method]. ( Ariyoshi, H; Hamajima, N; Hotta, T; Kodera, Y; Murate, T; Naito, K; Naoe, T; Ogura, M; Saito, H; Tanaka, M, 1994)
"Fluconazole was evaluated prospectively in 173 children aged between 4 months and 16 years in whom conventional antifungal therapy was ineffective or contraindicated."	2.67	Fluconazole treatment of children with severe fungal infections not treatable with conventional agents. ( Fasano, C; Gibbs, D; O'Keeffe, J, 1994)
"Fluconazole was evaluated prospectively in 40 neonates and infants between the ages of 2 days and 3 months in whom conventional antifungal therapy was ineffective or contraindicated."	2.67	Fluconazole treatment of neonates and infants with severe fungal infections not treatable with conventional agents. ( Fasano, C; Gibbs, D; O'Keeffe, J, 1994)
"Oral fluconazole was used as initial therapy in all patients, which was followed by catheter removal if peritonitis failed to improve."	2.67	Treatment of fungal peritonitis complicating continuous ambulatory peritoneal dialysis with oral fluconazole: a series of 21 patients. ( Chan, CY; Chan, TM; Cheng, IK; Cheng, SW; Lo, CY; Lo, WK, 1994)
"Fluconazole (FLU) is a new antifungal agent that has been used successfully to treat Candida infections and has modest activity against aspergillosis in animal models."	2.67	Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. ( Anaissie, EJ; Bodey, GP; Elting, LS; Estey, E; Kantarjian, H; O'Brien, S, 1994)
"Fluconazole was particularly effective in reducing the carriage of C."	2.67	The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients. Bone Marrow Transplantation Team. ( Chandrasekar, PH; Gatny, CM, 1994)
"Fluconazole (FLCZ) is an antifungal agent of triazole class and has been proven to be effective against deep-seated mycosis caused by Candida spp."	2.67	[Experience of fluconazole granules and injection in pediatric patients]. ( Azuma, E; Ido, M; Ihara, T; Ito, M; Kamiya, H; Nakano, T; Sakurai, M; Yasuda, N, 1994)
"Fluconazole (FLCZ) is an antifungal agent of triazole class developed by Pfizer, Inc."	2.67	[A clinical study of fluconazole-granules and -injectable in pediatric patients with deep-seated mycoses]. ( Fujii, R; Hatae, Y; Ishikawa, Y; Kobayashi, M; Matsumoto, S; Sakiyama, Y; Sunakawa, K; Takase, A; Takeda, T; Yokota, T, 1993)
"Fluconazole (FLCZ) was administered orally or intravenously to 161 patients with systemic fungal infections complicated with hematological disorders and it was possible to evaluate clinical efficacies in 109 patients."	2.67	[Clinical study of fluconazole for systemic fungal infections with hematological disorders]. ( Aoki, I; Kitamura, S; Miyakawa, K; Ohbayashi, Y; Sato, H; Shindo, E; Takaku, F; Togawa, A; Urabe, A; Wakabayashi, Y, 1993)
"Fluconazole or placebo was administered prophylactically from the start of the conditioning regimen until the neutrophil count returned to 1000 per microliter, toxicity was suspected, or a systemic fungal infection was suspected or proved."	2.67	A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. ( Chandrasekar, PH; Fox, B; Friedman, DJ; Goodman, JL; Greenfield, RA; Kaizer, H; Shadduck, RK; Shea, TC; Stiff, P; Winston, DJ, 1992)
"Fluconazole was as effective as amphotericin B in preventing severe local and disseminated fungal disease (one documented and one highly suspected infection in each group of patients)."	2.67	A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukaemia. ( Branger, J; Dekker, AW; Rozenberg-Arska, M; Verhoef, J, 1991)
"Fluconazole is a new orally absorbed antifungal azole which is effective in the treatment of mucosal and systemic infections caused by Candida, cryptococci and other fungi."	2.67	Management of fungal infection in neutropenic patients with fluconazole. ( Brammer, KW, 1990)
"The epidemiology of invasive fungal infections (IFIs) in immunocompromised individuals has changed over the last few decades, partially due to the increased use of antifungal agents to prevent IFIs."	2.66	Breakthrough invasive fungal infections: Who is at risk? ( Chen, SC; Cornely, OA; Hoenigl, M; Jenks, JD; Thompson, GR, 2020)
"Invasive fungal infections are a potentially life-threatening complication in immunocompromised patients."	2.66	Efficacy and safety of posaconazole for the prevention of invasive fungal infections in immunocompromised patients: a systematic review with meta-analysis and trial sequential analysis. ( Ching, SM; Divya, G; Loo, YS; Menon, RK; Veettil, SK; Wong, PS; Wong, TY, 2020)
"Fluconazole is a novel antifungal agent, available in oral and intravenous forms, which was developed by Pfizer Central Research."	2.66	[Clinical study of fluconazole on deep-seated fungal infections]. ( Akahonai, Y; Ikemoto, H; Kasai, M; Kawamura, K; Mikuni, C; Mori, T; Taniuchi, A; Watanabe, K; Yoshida, K; Yoshida, T, 1989)
"Fluconazole (UK-49,858) is a new bis-triazole antifungal drug that can be administered both orally and intravenously."	2.66	A prospective study of the efficacy of fluconazole (UK-49,858) against deep-seated fungal infections. ( Mattie, H; van Furth, R; Van't Wout, JW, 1988)
"Invasive fungal diseases (IFD) are associated with considerable morbidity and mortality in patients with hematological malignancies."	2.55	[Current Status and Future Perspectives of Primary Antifungal Prophylaxis in Patients with Hematological Malignancies-Review]. ( Li, Y; Yu, L, 2017)
"Voriconazole was dominated by posaconazole."	2.53	Network Meta-analysis and Pharmacoeconomic Evaluation of Fluconazole, Itraconazole, Posaconazole, and Voriconazole in Invasive Fungal Infection Prophylaxis. ( Chai, LY; Khoo, AL; Lim, BP; Ong, B; Tan, BH; Tan, G; Tee, C; Teng, M; Zhao, YJ, 2016)
" Based on currently available data, some antifungals should be dosed based on total body weight (i."	2.53	Dosing of antifungal agents in obese people. ( Hall, RG; Payne, KD, 2016)
"Invasive fungal infections are important causes of morbidity and mortality among critically ill patients."	2.53	Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients. ( Attanasio, M; Cortegiani, A; Giarratano, A; Maggiore, A; Naro, AR; Raineri, SM; Russotto, V, 2016)
" However, the duration and dosing of this prophylaxis treatment remain controversial."	2.53	Duration and intensity of fluconazole for prophylaxis in preterm neonates: a meta-analysis of randomized controlled trials. ( Che, D; Li, T; Wu, B; Zhou, H, 2016)
" Advances in pharmacokinetics (PK) and pharmacodynamics (PD) of antimicrobial medications have led to improved dosing guidance for neonates."	2.52	New antifungal and antiviral dosing. ( Monk, HM; Wade, KC, 2015)
" Both agents are safe without significant toxicities."	2.48	Chemoprophylaxis of neonatal fungal infections in very low birthweight infants: efficacy and safety of fluconazole and nystatin. ( Barzi, F; Blyth, CC; Hale, K; Isaacs, D, 2012)
"Invasive fungal infections are an important cause of morbidity and mortality in SOT and HSCT recipients."	2.48	[Prophylaxis against fungal infections in solid organ and hematopoietic stem cells transplantation]. ( Rabagliati, R; Santolaya, ME, 2012)
"Fluconazole plays an excellent role in prophylaxis, empirical therapy, and the treatment of both superficial and invasive yeast fungal infections."	2.47	Triazole antifungal agents in invasive fungal infections: a comparative review. ( Lass-Flörl, C, 2011)
"Fluconazole was given empirically, but had no effect."	2.45	Fluconazole-resistant Kodamaea ohmeri fungemia associated with cellulitis: case report and review of the literature. ( Hou, SJ; Lee, SY; Lu, JJ; Peng, MY; Sun, JR; Yang, BH, 2009)
"Micafungin is a new lipopeptide antifungal agent of the echinocandin class."	2.44	[Clinical efficacies of antifungal injections]. ( Fujii, Y; Inase, N; Yoshizawa, Y, 2008)
"Fungal peritonitis is a rare but serious complication in children on peritoneal dialysis (PD)."	2.44	Fungal peritonitis in children on peritoneal dialysis. ( Cornelissen, E; Monnens, L; Raaijmakers, R; Schröder, C; Warris, A, 2007)
" Two trials compared different dosing regimens of prophylactic intravenous fluconazole."	2.44	Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants. ( Austin, N; Clerihew, L; McGuire, W, 2007)
"Therapeutic drug monitoring of any pharmacologic agent should be considered when there is both significant pharmacokinetic variability and strong, clinically relevant, exposure-effect relationships."	2.44	Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. ( Andes, D; Smith, J, 2008)
"Voriconazole is a second-generation triazole antifungal agent, structurally derived from fluconazole with an extended spectrum of activity against a wide variety of yeasts and moulds."	2.43	Voriconazole: review of a broad spectrum triazole antifungal agent. ( Kofla, G; Ruhnke, M, 2005)
" Consequently, azoles interact with a vast array of compounds."	2.43	Drug-drug interactions of antifungal agents and implications for patient care. ( Amsden, JR; Gubbins, PO, 2005)
"Fungal infections are often challenging to manage, given the limited numbers of therapeutics and a general lack of applicable clinical literature for their use in a given animal species."	2.43	An overview of antifungal drugs and their use for treatment of deep and superficial mycoses in animals. ( Hector, RF, 2005)
"Invasive fungal infections have been noted in increasing frequency in immunosuppressed patients and may be due to organisms that are less susceptible or frankly resistant to antifungal agents."	2.41	Fungal susceptibility testing: where are we now? ( Patterson, TF, 2002)
"Fluconazole is approved for the treatment of candidal UTIs, but dosage recommendations are not consistent."	2.41	Fluconazole dose recommendation in urinary tract infection. ( Boedeker, KS; Kilzer, WJ, 2001)
"Amphotericin B has a broad spectrum and has remained the drug of choice for these life threatening invasive fungal infections."	2.41	[Choice and use of antifungal drugs]. ( Dupont, B, 2001)
"Opportunistic mycoses have emerged as important causes for morbidity and mortality in pediatric cancer patients, particularly in those with intensively treated hematological malignancies, allogeneic hematopoetic stem cell transplantation, and aplastic anemia."	2.41	[Prevention of fungal infections in children and adolescents with cancer]. ( Groll, AH; Müller, FM; Ritter, J, 2001)
"Patients with cancer complicated by neutropenia."	2.40	Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. ( Gøtzsche, PC; Johansen, HK, 1997)
"Invasive fungal infections are one of the leading causes of morbidity and mortality in cancer patients."	2.40	Antifungal treatment in patients with cancer. ( Castagnola, E; Machetti, M; Viscoli, C, 1997)
"However, Candida infections are predominantly caused by colonizing fungi; therefore drug prophylaxis is more promising."	2.40	Prophylaxis of fungal infections. ( Haag, C; Schuler, US, 1997)
" Whilst this pharmacokinetic profile is valuable in the treatment of fungal infections of the urinary tract, it also means that the dosage may need to be decreased in patients with renal impairment."	2.40	Fluconazole: comparison of pharmacokinetics, therapy and in vitro susceptibility. ( Laufen, H; Schmalreck, AF; Wildfeuer, A; Yeates, RA; Zimmermann, T, 1997)
" The maximum dosage used was 750 mg/d or 50 mg/kg BW in premature infants."	2.40	Role of fluconazole in the long-term suppressive therapy of fungal infections in patients with artificial implants. ( Penk, A; Pittrow, L, 1999)
" However, bioavailability of itraconazole is reduced in patients with raised gastric pH and no i."	2.39	[Prophylaxis against mycoses in neutropenic patients]. ( Arning, M; Aul, C, 1994)
"Treatment with amphotericin B was successful."	2.39	Disseminated Penicillium marneffei infection as an imported disease in HIV-1 infected patients. Description of two cases and a review of the literature. ( Blaauwgeers, JL; Dirks-Go, S; Kok, I; Rietra, PJ; Veenstra, J; Weigel, HM, 1994)
"Fluconazole is a triazole antifungal agent which is now an established part of therapy in patients with immune deficiencies."	2.39	Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. ( Barradell, LB; Goa, KL, 1995)
" Optimal dosing of either antifungal agent has not been defined in the studies."	2.39	Antifungal prophylaxis in bone marrow transplant. ( Althaus, BL; Lam, HH, 1995)
"Fungal infections have emerged as a major complication of marrow transplantation in children."	2.39	Evolving concepts of prevention and treatment of invasive fungal infections in pediatric bone marrow transplant recipients. ( Chanock, SJ; Walsh, TJ, 1996)
" Although this pharmacokinetic profile favours the use of fluconazole in mycotic infections of the urinary tract it also means that the dose of the drug may have to be adapted to lower regimens in the systemic treatment of patients with restricted kidney function."	2.39	[Fluconazole: comparison of pharmacokinetics, therapy and in vitro susceptibility of yeasts]. ( Laufen, H; Schmalreck, AF; Wildfeuer, A; Yeates, RA; Zimmermann, T, 1996)
" Besides the proven susceptibility of the fungus, clinical response to antifungal therapy with fluconazole also depends to a great extent on the daily dosage and the corresponding plasma and tissue concentrations as well as the immunological status and the underlying disease of the patient."	2.39	[Plasma and tissue concentrations of fluconazole: discussion of the breakpoint problem]. ( Penk, A; Pittrow, L, 1996)
"Fluconazole is a new systemic azole antifungal agent, with the imidazole group substituted by a triazole, presenting a decrease in lipophilicity, soluble in water, weakly bound to plasma proteins, and a wide range of formulations."	2.38	Fluconazole: pharmacokinetics and indications. ( Montero-Gei, F, 1993)
"Ketoconazole has proven useful in therapy for superficial infections and invasive infections caused by the pathogenic fungi."	2.38	Azole antifungal agents. ( Bodey, GP, 1992)
" Liposomal Amphotericin B allowing higher dosage by lower toxicity appears effective as salvage treatment especially in aspergillosis which also responds to Itraconazole available as oral formulation so far."	2.38	Antifungal treatment strategy in leukemia patients. ( Büchner, T; Roos, N, 1992)
"Fluconazole is a recently approved agent for the treatment of certain fungal infections."	2.38	Fluconazole: a new triazole antifungal agent. ( Morrow, JD, 1991)
"Ketoconazole was the first drug sufficiently potent and benign to permit use for both superficial and deep fungal infections."	2.38	Fungal infections and their management. ( Graybill, JR; Sharkey, PK, 1990)
"Fluconazole is a triazole antifungal agent labeled for use in the treatment of oropharyngeal and esophageal candidiasis and cryptococcal meningitis."	2.38	Fluconazole: a new antifungal agent. ( Dixon, DM; Kowalsky, SF, 1991)
"Fluconazole appears to be a highly promising agent due its highly favorable pharmacokinetic profile; it is water soluble, is well tolerated, is not metabolized to inactive constituents, it has a long half-life and, unlike the other azoles, high cerebrospinal fluid levels are readily attained for consideration in meningeal mycoses."	2.38	New antifungal agents for the systemic mycoses. ( Ringel, SM, 1990)
"I have tried to use the AIDS commentaries to keep up with these advances."	2.38	Azoles and AIDS. ( Larsen, RA, 1990)
"Invasive fungal infections are common in immunocompromised patients."	2.38	[Systemic mycotic infections]. ( Meunier, F, 1990)
"Fluconazole is a bis-triazole antifungal drug with novel pharmacokinetic properties (metabolic stability, relatively high water solubility) which contribute to its therapeutic activity."	2.38	Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. ( Clissold, SP; Grant, SM, 1990)
"Invasive fungal infections are major problems in immunocompromised patients and optimal therapeutical modalities are still far from optimal."	2.38	[Current progress in antifungal therapy: the value of fluconazole]. ( Meunier, F, 1990)
"Fluconazole is a fluorine-substituted, bis-triazole antifungal agent."	2.38	Fluconazole: a new triazole antifungal agent. ( Pasko, MT; Piscitelli, SC; Van Slooten, AD, 1990)
"Systemic fungal infections are life-threatening diseases that are occurring with increasing frequency, especially in immunocompromised patients."	2.37	Recent advances in the treatment of systemic fungal infections. ( Walsh, TJ, 1987)
" Most responders did not follow the strategies of voriconazole dosage based on CYP2C19 genotyping."	1.91	A survey to describe common practices on antifungal monitoring among Spanish clinicians. ( Gómez-López, A; Martín-Gómez, MT; Salavert Lletí, M, 2023)
"As a mainstay of treatment for acute lymphoblastic leukemia (ALL), vincristine's side effect profile is well known."	1.91	Vincristine Side Effects With Concomitant Fluconazole Use During Induction Chemotherapy in Pediatric Acute Lymphoblastic Leukemia. ( Beck, J; Cave, C; Ford, J; High, R; Ramirez, R; Raulji, C, 2023)
" It is observed that superficial fungal infections are treated by conventional dosage forms, which are incapable of treating deep infections due to the barrier activity possessed by the stratum corneum of the skin."	1.72	Novasomes as Nano-Vesicular Carriers to Enhance Topical Delivery of Fluconazole: A New Approach to Treat Fungal Infections. ( Abbas, G; Abourehab, MAS; Ahmed, MM; Almoshari, Y; Alshamrani, M; Chauhdary, Z; Fatima, I; Islam, N; Khames, A; Mehmood Khan, S; Naguib, DM; Namazi, NI; Rasul, A; Saadullah, M; Salawi, A; Shah, S, 2022)
"When mycoses are diagnosed early and treated with the appropriate drugs, favorable therapeutic outcomes can be achieved."	1.72	Fungal esophagitis associated with tuberculous pericarditis in an human immunodeficiency virus-positive patient: a case report. ( de Lima-Neto, RG; de Melo, HRL; de Sousa, BR; Neves, RP; Silva, GM; Torres, KB, 2022)
"Candidiasis is reported to be the most common fungal infection in the critical care setting."	1.72	Mathematical Modeling of Fluconazole Resistance in the Ergosterol Pathway of ( Lao, AR; Moron-Espiritu, LS; Yu, PK, 2022)
" According to our study, resveratrol can reduce the dosage to 1/64 of ketoconazole as well as itraconazole."	1.62	The synergistic antifungal activity of resveratrol with azoles against Candida albicans. ( Gao, L; Song, F; Wan, Y; Wang, J; Wang, L; Zhang, L; Zhang, X, 2021)
" In fact, certain drugs may interact in ways that make treatment less effective."	1.56	Synergistic and antagonistic drug interactions in the treatment of systemic fungal infections. ( Ayala, M; Brammer, B; Brown, JC; Denham, ST; Stonhill, MA; Wambaugh, MA, 2020)
"Candida pericarditis is a rare condition with high mortality."	1.48	A case report of purulent pericarditis caused by Candida albicans: Delayed complication forty-years after esophageal surgery. ( Feinstein, A; Perez, IE; Stein, DK; Sung, J, 2018)
"The fungal esophagitis in patients with hematologic malignancies was not rare."	1.43	[A clinical study of fungal esophagitis in 13 patients with hematologic malignancies]. ( Ai, H; Li, YF; Liu, YY; Mi, RH; Song, YP; Wei, XD; Zhang, LN; Zhou, YL, 2016)
" The immunosuppression dosing in conjunction with azole use at discharge was analyzed to develop a dosing algorithm dependent on whether fluconazole, posaconazole, or voriconazole was used."	1.42	Dosing algorithm for concomitant administration of sirolimus, tacrolimus, and an azole after allogeneic hematopoietic stem cell transplantation. ( Fung, HC; Peksa, GD; Schultz, K, 2015)
"Posaconazole has shown superior clinical efficacy in the prevention of invasive fungal disease (IFD) among neutropenic patients as well as cost-effectiveness in the US healthcare setting vs fluconazole or itraconazole (FLU/ITRA) based on oral suspension formulations of each therapy."	1.42	An update to the cost-effectiveness of posaconazole vs fluconazole or itraconazole in the prevention of invasive fungal disease among neutropenic patients in the United States. ( Marcella, SW; Sung, AH; Xie, Y, 2015)
"Posaconazole was introduced as the primary antifungal prophylaxis (PAP) in acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) patients during remission induction chemotherapy."	1.42	Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations. ( Cho, SY; Choi, JH; Choi, JK; Choi, SM; Kim, HJ; Kim, SH; Kim, YJ; Lee, DG; Lee, HJ; Min, WS; Park, SH; Yoo, JH, 2015)
"Fluconazole prophylaxis was accompanied by a significant decrease in both the rate and number of days of bacterial infections as well as co-infections."	1.40	Fluconazole prophylaxis is associated with a decreased rate of coagulase-negative Staphylococcal infections in a subset of extremely low birth weight neonates. ( Abou Jaoude, R; DeBari, VA; Lamacchia, M; McClure, D; Morel, C; Zauk, A, 2014)
"Fluconazole (0."	1.39	Minimal trephination penetrating keratoplasty for severe fungal keratitis complicated with hypopyon. ( He, B; Jia, H; Liu, Y; Ning, Y; Shi, X; Wang, C; Wang, J; Zheng, X, 2013)
"Fungal infections are a common cause of late-onset sepsis in very low birth weight infants and can impact mortality and morbidity."	1.39	Mortality and risk factors for invasive fungal infections after the implementation of a fluconazole prophylaxis protocol in very low birth weight infants. ( Acosta, AM; García-Fragoso, L; García-García, I; Reyes, G; Rivera, J; Valcárcel, M, 2013)
"There were 91 patients with acute myeloid leukemia (AML), 51 with acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL), and 68 with ATL."	1.39	Distinct clinical features of infectious complications in adult T cell leukemia/lymphoma patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis in the Nagasaki transplant group. ( Ando, K; Fukushima, T; Hata, T; Honda, S; Imaizumi, Y; Imanishi, D; Itonaga, H; Matsuo, E; Miyazaki, Y; Moriuchi, Y; Onimaru, Y; Sato, S; Sawayama, Y; Taguchi, J; Tsushima, H; Yamasaki, R; Yoshida, S, 2013)
"Fluconazole is an antifungal agent that is commonly used to treat patients with serious systemic fungal infections in intensive care units."	1.38	Population pharmacokinetics of fluconazole after administration of fosfluconazole and fluconazole in critically ill patients. ( Aoyama, T; Hayashi, H; Hirata, K; Hirata, R; Matsumoto, Y; Yamamoto, Y; Yamazaki, H, 2012)
"Neonatal fungal infections are associated with substantial mortality and morbidity."	1.38	European survey on the use of prophylactic fluconazole in neonatal intensive care units. ( Bonati, M; Choonara, I; Jacqz-Aigrain, E; Kaguelidou, F; Manzoni, P; Pandolfini, C, 2012)
"Post-induction aplasia for acute myeloid leukemia/myelodysplastic syndrome is a high-risk period for invasive fungal diseases."	1.38	Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. ( Ananda-Rajah, MR; Bajel, A; Cheng, A; Downey, MT; Grigg, A; Slavin, MA; Spelman, T; Thursky, KT; Vincent, J, 2012)
"Fluconazole was more frequently used in medium size hospitals than in the large ones (60."	1.38	[Trends in systemic antifungal use in critically ill patients. Multicenter observational study, 2006-2010]. ( Alvarez-Lerma, F; Gimeno-Costa, R; Gracia-Arnillas, MP; Insausti-Ordeñana, J; López-Pueyo, MJ; Olaechea-Astigarraga, PM; Otal-Entraigas, JJ; Palomar-Martínez, M; Seijas-Betolaza, I, 2012)
"001), and a daily prophylactic fluconazole dosage < 200 mg (OR = 2."	1.38	Invasive fungal infections following liver transplantation: incidence, risk factors, survival, and impact of fluconazole-resistant Candida parapsilosis (2003-2007). ( Butler, S; Cooley, J; Hardy, D; Koval, CE; Orloff, M; Raghuram, A; Restrepo, A; Safadjou, S, 2012)
" The occurrence of LAMB-attributable renal toxicity was investigated; infants withdrawn from treatment for development of adverse effects or toxicity were identified."	1.38	Liposomal amphotericin B does not induce nephrotoxicity or renal function impairment in premature neonates. ( Antonucci, R; Fanos, V; Farina, D; Franco, C; Galletto, P; Gallo, E; Manzoni, P; Rizzollo, S, 2012)
"Posaconazole was associated with an overall cost savings (range = $Can1,765 to $Can4,505) in all of the scenarios evaluated."	1.37	Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis. ( Dranitsaris, G; Khoury, H, 2011)
"One patient developed trichosporonosis while on caspofungin and the other became infected/ colonised with Candida glabrata that was resistant to voriconazole and posaconazole."	1.37	Selection of resistant fungi in liver transplant recipients during use of newer antifungal agents -- a report of two cases. ( Lingegowda, PB; Tan, AL; Tan, BH; Tan, CK, 2011)
"Disseminated fungal infections are common presenting opportunistic infections among AIDS patients in developing countries."	1.37	Itraconazole vs fluconazole as a primary prophylaxis for fungal infections in HIV-infected patients in Thailand. ( Boonmee, D; Chaiwarith, R; Fakthongyoo, A; Praparattanapan, J; Sirisanthana, T; Supparatpinyo, K, 2011)
"Posaconazole was associated with fewer IFIs (5."	1.36	Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT. ( Carreras, E; Casado, MA; de la Cámara, R; Grau, S; Jarque, I; Sabater, FJ; Sanz, MA, 2010)
"Fluconazole prophylaxis was administered following 44 cycles (fluconazole group) and not given in 32 cycles (control group)."	1.36	Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high-dose cytarabine consolidations and thus do not require prophylaxis. ( Deremer, D; Dobbins, R; Eisa, N; El-Geneidy, M; Hall, P; Jillella, A; Lewis, G; Ustun, C, 2010)
"Isavuconazole (BAL4815) is a promising novel broad-spectrum triazole in late-stage clinical development that has proven active in vitro against Aspergillus and Candida species."	1.35	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. ( Bouza, E; Guinea, J; Peláez, T; Recio, S; Torres-Narbona, M, 2008)
"Micafungin was active against species of Candida and Aspergillus (even azole-resistant species) as well as Penicillium spp."	1.35	Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. ( Buitrago, MJ; Cuenca-Estrella, M; Gomez-Lopez, A; Mellado, E; Monzon, A; Rodriguez-Tudela, JL, 2009)
"Tacrolimus doses were adjusted to achieve concentrations of 5-20 ng/mL."	1.35	Effect of aprepitant on intravenous tacrolimus disposition in reduced intensity hematopoietic stem cell transplantation. ( Abidi, MH; Ayash, LJ; Cadotte, C; Cronin, SM; Edwards, DJ; Ibrahim, RB; Jacobson, PA; Mulawa, J; Smith, DW; Uberti, JP, 2008)
"Invasive fungal infections are a leading cause of mortality among immunocompromised individuals."	1.35	Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. ( Aziz, H; Collins, C; Cowen, LE; Köhler, JR; Lindquist, S; Mylonakis, E; Perfect, JR; Schell, WA; Singh, SD; Whitesell, L; Zaas, AK, 2009)
"Micafungin was a cost-effective prophylactic antifungal strategy by providing lower medical costs and longer life expectancy than fluconazole from the payer's perspective in a hypothetical cohort of Korean adults undergoing HSCT."	1.35	Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea. ( Kim, D; Kim, J; Lee, TJ; Sohn, HS, 2009)
"Fungal spondylodiskitis (inflammation of intervertebral disk tissue and adjacent vertebrae) is rare, particularly in immunocompetent patients."	1.35	Fungal thoracic Spondylodiskitis in an immunocompetent 14-year-old girl. ( Aki, K; Asano, T; Fujino, O; Hatori, T; Kuwabara, K, 2009)
"To report the first case of T."	1.35	Postoperative Trichosporon asahii spondylodiscitis after open lumbar discectomy: a case report. ( Choi, SM; Ha, KY; Kim, KW; Kim, MS; Lee, JS, 2008)
"Fungal peritonitis is a rare but serious complication in children on peritoneal dialysis."	1.35	Acremonium spp. peritonitis in an infant. ( Atalay, S; Ciftçi, E; Düzenli, F; Ekim, M; Galip, N; Güriz, H; Kendirli, T; Ozçakar, ZB; Tapisiz, A; Tutar, E; Uçar, T, 2008)
" A potentially drug-drug interaction (DDI) occurred when the use of concomitant drugs were recorded within +/-30 days from the date of the first azoles prescription."	1.34	Co-prescriptions with itraconazole and fluconazole as a signal for possible risk of drug-drug interactions: a four-year analysis from Italian general practice. ( Caputi, AP; Cricelli, C; Galatti, L; Greco, A; Mazzaglia, G; Nicoletti, G; Schito, GC; Sessa, E; Spina, E, 2007)
"Fluconazole permeation was high (15-65% of the applied dose) across hairless mouse skin and low (8-9%) across pig ear skin."	1.34	Topical delivery of fluconazole: in vitro skin penetration and permeation using emulsions as dosage forms. ( Ayub, AC; Ferreira, LA; Gomes, AD; Lima, MV; Vianna-Soares, CD, 2007)
"While an AZ-based regimen is associated with increased cost, the reduced rate of nephrotoxicity and availability of oral dosage forms, suggests that azoles be used preferentially over AMB."	1.34	Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study. ( Choe, L; Guglielmo, BJ; Inciardi, J; Martin, T; Riedel, A; Yuen, C, 2007)
" We recorded the concomitant use of medications known to interact with azole antifungals and measured the frequency of potential azole drug interactions, which we considered to be present when both drugs were given together."	1.33	Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions. ( Bates, DW; Gerth, WC; Peterson, JF; Seger, DL; Yu, DT, 2005)
"Fungal infections have increased dramatically in recent years and candidemia is a major risk factor for morbidity and mortality in intensive care units (ICUs)."	1.33	In vitro susceptibility of yeasts isolated from patients in intensive care units to fluconazole and amphotericin B during a 3-year period. ( Erturan, Z; Kucukates, E; Susever, S; Yegenoglu, Y, 2005)
"As soon as osteomyelitis is suspected, investigations with MRI and percutaneous biopsy should be performed followed by medical therapy."	1.33	Candida albicans osteomyelitis of the spine: progressive clinical and radiological features and surgical management in three cases. ( Debnath, UK; Fares, Y; Khazim, RM, 2006)
"Invasive fungal infections are fatal complications for patients on chemotherapy, and antifungal prophylactic treatment has been commonly recommended."	1.33	Cost-effectiveness analysis of antifungal treatment for patients on chemotherapy. ( Kawasugi, K; Morimoto, T; Nomura, K, 2006)
"Posaconazole was the most active of antifungal agents tested against Aspergillus spp."	1.33	Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. ( Buitrago, MJ; Cuenca-Estrella, M; Gomez-Lopez, A; Mellado, E; Monzon, A; Rodriguez-Tudela, JL, 2006)
"Fluconazole was administered to 81% of ELBW infants, who received a median of 8 doses, and 41% of larger infants, who received a median of 5 doses."	1.33	Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants. ( Brion, LP; Dave, VA; Herring, L; Marsh, J; Nafday, S; Reinersman, GT; Soghier, LM; Uko, S; Vega, M, 2006)
"Posaconazole was active against isolates of Candida and Aspergillus spp."	1.33	In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. ( Black, TA; Hare, R; Loebenberg, D; Mann, PA; McNicholas, PM; Mendrick, CA; Norris, CC; Patel, R; Sabatelli, F, 2006)
"Fungal infections have become one of the emerging complications in intensive care patients and the morbidity and mortality linked to these infections underlines the importance of managing these pathologies."	1.32	High-dose fluconazole therapy in Intensive Care Unit. ( Bacigalupo, P; Bonfiglio, M; Buscaglia, G; De Bellis, P; Gerbi, G; Guido, P; Massobrio, B, 2003)
"Fluconazole was the least effective in vitro."	1.32	In vitro activity of amphotericin B, itraconazole, terbinafine and 5-fluocytosine against Exophiala spinifera and evaluation of post-antifungal effects. ( De Hoog, GS; Verweij, PE; Vitale, RG, 2003)
"This study of patients with advanced cancer has demonstrated a high incidence of oral colonization with non-C."	1.32	High prevalence of non-albicans yeasts and detection of anti-fungal resistance in the oral flora of patients with advanced cancer. ( Al, MA; Bagg, J; Baxter, W; Coleman, D; Jackson, MS; Lewis, MA; McEndrick, S; McHugh, S; Sweeney, MP, 2003)
"Oral candidiasis is the most common manifestation, superficial cutaneous infections of the dermis are rarely seen."	1.32	Generalized fungal infection in a patient with AIDS appearing as skin papules. ( Altmeyer, P; Brockmeyer, NH; Kreuter, A; Stuecker, M; Teichmann, M; Tietz, HJ, 2003)
"Peritonitis is a frequent complication in patients with chronic renal failure on continuous ambulatory peritoneal dialysis (CAPD) treatment."	1.32	Fungal peritonitis in 15 patients on continuous ambulatory peritoneal dialysis (CAPD). ( González-Monroy, J; Hernández-Hernández, F; López-Martínez, R; Manzano-Gayosso, P; Méndez-Tovar, LJ, 2003)
"The tacrolimus dose was empirically reduced by approximately one-third when azole therapy was initiated."	1.32	Tacrolimus dosage requirements after initiation of azole antifungal therapy in pediatric thoracic organ transplantation. ( Boyle, GJ; Gandhi, S; Kurland, G; Law, YM; Mahnke, CB; Michaels, M; Miller, SA; Pigula, FA; Sutton, RM; Venkataramanan, R; Webber, SA, 2003)
" Number of patients who received the dosage recommended in the CDC guidelines (400 mg/day) was 135 (42%) in conventional transplant and 34 (30%) in RIST (P=0."	1.32	A nationwide survey of deep fungal infections and fungal prophylaxis after hematopoietic stem cell transplantation in Japan. ( Adachi, Y; Anan, K; Fukuhara, T; Gotoh, M; Hamaguchi, M; Hashino, S; Higuchi, M; Imataki, O; Inoue, T; Kami, M; Kasai, M; Kawakami, K; Kim, SW; Kobayashi, Y; Komaba, S; Masuda, M; Naito, K; Nishimura, M; Takaue, Y; Teshima, H; Togitani, K; Uike, N; Yamashita, T, 2004)
"Treatment with fluconazole alone has an effect comparable to intraperitoneal (IP) amphotericin B alone or IP amphotericin B combined with oral or intravenous fluconazole."	1.32	Fungal peritonitis in peritoneal dialysis patients: effect of fluconazole treatment and use of the twin-bag disconnect system. ( Chen, CM; Ho, MW; Wang, JH; Yu, WL, 2004)
"Fluconazole was the antifungal agent most frequently used, both in infected and colonized patients."	1.32	[Indications for antifungal treatment in intensive care unit patients]. ( Alvarez-Lerma, F; Bermejo, B; Cerdá, E; León, C; Olaechea, P; Palomar, M, 2004)
"Fungal peritonitis is a serious complication of chronic peritoneal dialysis (CPD) and is frequently associated with CPD drop-out."	1.31	Paecilomyces variotii peritonitis in an infant on automated peritoneal dialysis. ( Fiscarelli, E; Rinaldi, S; Rizzoni, G, 2000)
" Drug safety and efficacy were assessed before each dosage reduction."	1.31	Targeted prophylaxis with amphotericin B lipid complex in liver transplantation. ( Ellis, RW; Fisher, NC; Hastings, JG; Jones, SG; Miller, SJ; Mutimer, DJ; Singhal, S, 2000)
"Voriconazole is a promising azole effective against a variety of fungi, including yeasts."	1.31	Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish University Hospital and effect of time of reading. ( Arikan, S; Kocagöz, S; Sancak, B; Unal, S; Uzun, O, 2000)
"Fungal peritonitis is rarely encountered."	1.31	Trichosporon beigelii peritonitis in a HIV-positive patient on continuous ambulatory peritoneal dialysis. ( Agarwal, SK; Anuradha, S; Bajaj, J; Chatterjee, A; Kaur, R; Singh, NP, 2000)
"Diagnosis and treatment of fungal infections in medical and surgical intensive care units are controversial issues."	1.31	[Fungal infections in intensive care units: a cross-survey]. ( Dupont, H, 2001)
" However, important issues for improvement could be identified, such as increasing the dosage and duration of treatment in cases of serious infections, and withholding treatment from patients with colonization rather than infection."	1.31	Use of fluconazole in daily practice: still room for improvement. ( Hekster, YA; Kullberg, BJ; Meis, JF; Natsch, S; Steeghs, MH; van der Meer, JW, 2001)
"Local lesions observed in otitis, create favourable conditions for the growth of fungi and development of mycoses both in the external and middle ear, as well as in post-operative cavities, especially in cases of open-type surgery."	1.31	Otomycosis: prevalence, clinical symptoms, therapeutic procedure. ( Filipiak, A; Kurnatowski, P, 2001)
"Fusarium solani was cultured from the initial vitrectomy specimen in patient 1, and although it was not cultured from the keratitis, septate hyphal elements were present on histopathologic examination."	1.30	Delayed-onset fungal keratitis after endophthalmitis. ( Eagle, RC; Frayer, WC; Orlin, SE; Sulewski, ME; Weissgold, DJ, 1998)
" Conversion from cyclosporine to tacrolimus during maintenance therapy is often considered in the event of rejection or when adverse events do not respond to dosage reduction."	1.30	Suggested guidelines for the use of tacrolimus in pancreas/kidney transplantation. ( Bartlett, ST; Burke, GW; Gruessner, RW; Stock, PG, 1998)
"No fungal infections were observed during this period, and all patients provided negative cultures."	1.30	Antifungal prophylaxis during the early postoperative period of lung transplantation. Valencia Lung Transplant Group. ( Borro, JM; Calvo, V; Morales, P; Morcillo, A; París, F; Tarrazona, V; Vicente, R, 1999)
"Yeast fungemia has increased markedly in the last few years."	1.30	[A multicenter study on fungemia caused by yeasts in Spain (April-June, 1997). A Work Group to Study Fungemia)]. ( Cuenca-Estrella, M; Rodríguez-Tudela, JL, 1999)
"Fluconazole has proven efficacy in prophylaxis, treatment and suppressive therapy of both systemic and superficial fungal infections, especially in candidosis and cryptococcosis."	1.30	Therapeutic experience with fluconazole in the treatment of fungal infections in diabetic patients. ( Penk, A; Pittrow, L, 1999)
"Fungal infections are common in people with HIV/AIDS, especially among those with CD4+ counts below 200."	1.30	Fluconazole and fungal infections. ( , 1999)
"Fluconazole was most active against C."	1.29	In vitro susceptibilities of clinical yeast isolates to three antifungal agents determined by the microdilution method. ( Barry, AL; Pfaller, MA, 1995)
"Fluconazole was well tolerated systemically."	1.29	Oral fluconazole therapy for keratomycosis. ( Thakar, M, 1994)
"Fluconazole is a highly water-soluble, metabolically stable bis-triazole antifungal with excellent cerebrospinal fluid penetration and low toxicity."	1.29	Fluconazole therapy in a rhesus monkey (Macaca mulatta) with epidural Trichosporon beigelii in a cephalic recording cylinder. ( Dannemiller, SD; Rozmiarek, H; Watson, JR, 1995)
"Fluconazole was used most frequently across all sites of presumed or documented infections, with the exception of fungemia."	1.29	Use of antifungal therapy in hospitalized patients. II. Results after the marketing of fluconazole. ( Blackwelder, N; Bruder-Holt, RJ; Goodwin, SD; Grasela, TH; Pasko, MT; Walawander, CA, 1994)
" In conclusion, from a pharmacokinetic point of view, all the antifungal agents examined, perhaps with the exception of F, do not offer, when used alone, sufficient guarantees in curing peritonitis."	1.29	Pharmacokinetics of antifungal agents. ( Bolzonella, R; Contestabile, A; Fabris, A; Gardin, C; Pellanda, MV, 1993)
" Given the nephrotoxic potential of the immunosuppressant drug, dosage reduction and closer monitoring of cyclosporine concentrations and/or renal function in patients receiving fluconazole dosages greater than 200 mg/d must be considered."	1.29	Fluconazole-cyclosporine interaction: a dose-dependent effect? ( López-Gil, JA, 1993)
"Fluconazole is considered to be a potent, safe antifungal agent for the treatment of suspected fungal infection during intravenous hyperalimentation."	1.29	[Clinical studies of fluconazole in patients with deep-seated fungal infection in intravenous hyperalimentation (IVH)]. ( Arakawa, K; Kono, K; Takeda, S; Tatara, I, 1996)
"Fluconazole is considered to be a potent, safe antifungal agent for the treatment of suspected fungal infections associated with hematological diseases."	1.29	[Clinical efficacy of fluconazole against fungal infections in hematological diseases]. ( Asahara, F; Hisano, S; Kawasaki, C; Kimura, N; Morioka, E; Nagano, M; Nakashima, H; Okumura, M; Suzumiya, J; Uchida, T; Yoshida, T, 1996)
"Fluconazole (FLCZ) was administrated 100-400 mg/day intravenously or orally to 79 patients with systemic fungal infections complicated with hematological disorders and it was possible to evaluate clinical efficacies in 60 patients."	1.29	[A clinical evaluation of fluconazole in deep seated fungal infections associated with hematological disorders]. ( Asano, Y; Eto, S; Ikeda, K; Izumi, Y; Misago, M; Mori, N; Morimoto, I; Murakami, S; Nagata, K; Nakanishi, M; Nakata, K; Oda, E; Oda, S; Ogawa, R; Ohkuma, K; Ohmori, F; Ohnishi, Y; Sawada, H; Tanaka, H; Tohnai, S; Tsukada, J; Wake, A; Yamamura, M; Yamano, Y; Yamasaki, Y, 1996)
"Fluconazole 200 mg was given orally (po) as first dose at the onset of antibiotic therapy, then 100 mg po every other day, and was continued for one week after the antibiotic therapy."	1.29	Antifungal prophylaxis for secondary fungal peritonitis in peritoneal dialysis patients. ( Cabralda, T; Suh, H; Wadhwa, NK, 1996)
"The use of preventive treatment for fungal infections is cautioned due to the possibility of resistance to treatment."	1.29	Fungal infection overview. ( , 1995)
"Treatment with ketoconazole and potassium iodide did not prevent several relapses."	1.28	Rhinofacial zygomycosis caused by Conidiobolus coronatus. A case report. ( Costa, AR; Cucé, LC; dos Reis, VM; Lacaz, Cda S; Müller, H; Pegas, JR; Pires, MC; Porto, E; Rodrigues, MC, 1991)
"Fluconazole was administered orally at a daily dose of 100 mg and 200 mg, respectively (n = 29), or intravenously at a dose of 100 mg and 400 mg (n = 2)."	1.28	[Prophylaxis and therapy of fungal infections with fluconazole in patients after bone marrow transplantation]. ( Beelen, DW; Dermoumi, H; Kölbel, M; Kraft, J; Müller, KD; Quabeck, K; Schaefer, UW, 1990)
"Treatment with amphotericin B, flucytosine and high doses of fluconazole was followed by clinical improvement, although CSF pleocytosis remained."	1.28	First report of chronic meningitis caused by Trichosporon beigelii. ( Boogaerts, M; Marcelis, L; Surmont, I; Verbist, L; Vergauwen, B; Verhoef, G, 1990)
" capitatum are usually sensitive to the azole compounds the explanation may be a too low daily dosage for the treatment of severely immunocompromised hosts."	1.28	[Trichosporon capitatum septicemia in immunosuppressed patients]. ( Bergerat, JP; Dufour, P; Herbrecht, R; Koenig, H; Liu, KL; Maloisel, F; Oberling, F; Waller, J, 1990)
"Fluconazole is a novel triazole antifungal agent developed by Pfizer Inc."	1.28	[A clinical evaluation of fluconazole in the treatment of deep mycosis]. ( Hino, J; Moriya, O; Nakajima, M; Niki, Y; Soejima, R; Tsukiyama, K; Watanabe, M; Yagi, S, 1989)
"Fluconazole was markedly effective against septicemia due to Candida and oral candidiasis accompanied with lingual ulcer in spite of seriousness of these underlying disease."	1.28	[Clinical evaluation of fluconazole in patients with mycotic infection]. ( Adachi, M; Ikeda, H; Kawanishi, M; Matsushima, T; Nakamura, J; Tanabe, J; Tano, Y; Tomizawa, S, 1989)
"Fluconazole is a triazole agent and possesses a potent antifungal activity against fungi such as Candida, Cryptococcus and Aspergillus."	1.28	[Experience of fluconazole in pediatric patients]. ( Arai, S; Iguchi, K; Kamiya, H; Sakurai, M, 1989)
" No significant adverse reactions nor abnormality in clinical laboratory tests related with the dosing of fluconazole were observed in any of the patients."	1.28	[A clinical evaluation of injectable fluconazole in the treatment of deep mycosis associated with hematological malignancy]. ( Hojo, H; Lin, KY; Torii, Y; Toyama, K; Tsuda, A; Yoshikawa, O, 1989)
"Fluconazole is a triazole antifungal compound with a very original distribution to the meninges and urinary tract; it is mainly used in candidiasis and cryptococcosis."	1.28	[Treatment of mycoses and new antifungal agents]. ( Dupont, B, 1989)

Research

Studies (735)

Authors

Clinical Trials (31)

Trial Overview

Trial Outcomes

Overall Survival

Timeframe	Studies, this research(%)	All Research%
pre-1990	23 (3.13)	18.7374
1990's	242 (32.93)	18.2507
2000's	252 (34.29)	29.6817
2010's	173 (23.54)	24.3611
2020's	45 (6.12)	2.80

Authors	Studies
Serena, C	2
Rodríguez, MM	1
Mariné, M	1
Pastor, FJ	2
Guarro, J	2
Lortholary, O	3
Dannaoui, E	1
Raoux, D	1
Hoinard, D	1
Datry, A	1
Paugam, A	1
Poirot, JL	1
Lacroix, C	1
Dromer, F	1
Cuenca-Estrella, M	5
Gomez-Lopez, A	5
Gutierrez, MO	1
Buitrago, MJ	3
Rodriguez-Tudela, JL	5
Guinea, J	1
Peláez, T	1
Recio, S	1
Torres-Narbona, M	1
Bouza, E	3
Mitsuyama, J	1
Nomura, N	1
Hashimoto, K	1
Yamada, E	1
Nishikawa, H	1
Kaeriyama, M	1
Kimura, A	1
Todo, Y	1
Narita, H	1
Mellado, E	3
Monzon, A	2
Chen, SC	4
Biswas, C	1
Bartley, R	1
Widmer, F	1
Pantarat, N	1
Obando, D	1
Djordjevic, JT	1
Ellis, DH	1
Jolliffe, KA	1
Sorrell, TC	5
Yu, S	1
Chai, X	2
Hu, H	1
Yan, Y	2
Guan, Z	1
Zou, Y	2
Sun, Q	3
Wu, Q	2
Wang, XL	1
Wan, K	1
Zhou, CH	4
Zhang, J	2
Cao, Y	1
Zhang, D	1
Jiang, Y	1
Vijesh, AM	1
Isloor, AM	2
Telkar, S	1
Peethambar, SK	1
Rai, S	1
Isloor, N	1
Prakash, O	1
Aneja, DK	1
Hussain, K	1
Lohan, P	1
Ranjan, P	1
Arora, S	1
Sharma, C	2
Aneja, KR	1
Barbuceanu, SF	1
Saramet, G	1
Almajan, GL	1
Draghici, C	1
Barbuceanu, F	1
Bancescu, G	1
Wang, Y	2
Damu, GL	1
Lv, JS	1
Geng, RX	3
Yang, DC	1
Kathiravan, MK	1
Salake, AB	1
Chothe, AS	1
Dudhe, PB	1
Watode, RP	1
Mukta, MS	1
Gadhwe, S	1
Shelke, SH	1
Mhaske, PC	1
Nandave, M	1
Narkhade, S	1
Walhekar, NM	1
Bobade, VD	1
Sharma, V	1
Singh, G	1
Kaur, H	1
Saxena, AK	1
Ishar, MP	1
Patel, RV	1
Park, SW	1
Yin, BT	1
Yan, CY	1
Peng, XM	2
Zhang, SL	1
Rasheed, S	1
Chandrakantha, B	1
Shetty, P	1
Fun, HK	1
Hegde, G	1
Kotaiah, Y	1
Nagaraju, K	1
Harikrishna, N	1
Venkata Rao, C	1
Yamini, L	1
Vijjulatha, M	1
Krátký, M	1
Bősze, S	1
Baranyai, Z	1
Szabó, I	1
Stolaříková, J	1
Paraskevopoulos, G	1
Vinšová, J	1
Fosso, MY	1
Shrestha, SK	2
Green, KD	1
Garneau-Tsodikova, S	2
Nagamallu, R	1
Srinivasan, B	1
Ningappa, MB	1
Kariyappa, AK	1
Jeyakkumar, P	1
Liu, HB	1
Gopala, L	1
Cheng, Y	1
Garzan, A	1
Yates, CM	1
Garvey, EP	1
Shaver, SR	1
Schotzinger, RJ	1
Hoekstra, WJ	1
Emami, S	1
Ghobadi, E	1
Saednia, S	1
Hashemi, SM	1
Wang, SQ	1
Wang, YF	1
Xu, Z	1
Jin, YS	1
Mani Chandrika, KVS	1
Sharma, S	1
Ngoc Toan, V	1
Dinh Thanh, N	1
Minh Tri, N	1
Thi Thu Huong, N	1
Choi, JW	1
Lee, KT	1
Kim, S	1
Lee, YR	1
Kim, HJ	4
Seo, KJ	1
Lee, MH	1
Yeon, SK	1
Jang, BK	1
Park, SJ	1
Park, JH	1
Kim, D	3
Lee, DG	3
Cheong, E	1
Lee, JS	2
Bahn, YS	1
Park, KD	1
Hagras, M	1
Abutaleb, NS	1
Sayed, AM	1
Salama, EA	1
Seleem, MN	1
Mayhoub, AS	1
Hu, F	1
Wang, C	2
Wang, P	1
Zhang, L	2
Jiang, Q	1
Al-Hatmi, AMS	1
Blechert, O	1
Zhan, P	2
Kaeuffer, C	1
Baldacini, M	1
Ruge, T	1
Ruch, Y	1
Zhu, YJ	1
De Cian, M	1
Philouze, G	1
Bachellier, P	1
Denis, J	1
Lefebvre, N	1
Schneider, F	1
Hansmann, Y	1
Letscher-Bru, V	3
Herbrecht, R	3
Sabou, M	1
Danion, F	1
Liu, NN	1
Zhou, J	2
Jiang, T	1
Tarsio, M	1
Yu, F	1
Zheng, X	2
Qi, W	1
Liu, L	1
Tan, JC	1
Wei, L	1
Ding, J	1
Li, J	1
Zeng, L	1
Ren, B	1
Huang, X	2
Peng, Y	1
Cao, YB	1
Zhao, Y	1
Zhang, XY	1
Kane, PM	1
Chen, C	2
Wang, H	2
Fatima, I	1
Rasul, A	1
Shah, S	1
Saadullah, M	1
Islam, N	1
Khames, A	1
Salawi, A	1
Ahmed, MM	1
Almoshari, Y	1
Abbas, G	1
Abourehab, MAS	1
Mehmood Khan, S	1
Chauhdary, Z	1
Alshamrani, M	1
Namazi, NI	1
Naguib, DM	1
Chen, L	4
van Rhee, KP	1
Wasmann, RE	1
Krekels, EHJ	1
Wiezer, MJ	1
van Dongen, EPA	1
Verweij, PE	3
van der Linden, PD	1
Brüggemann, RJ	3
Knibbe, CAJ	1
Liu, Y	4
Lan, C	1
Qin, S	1
Qin, Z	1
Zhang, Z	1
Zhang, P	1
Cao, W	1
Sah, SK	1
Shariff, A	1
Pathakamuri, N	1
Ramaswamy, S	1
Ramesh, M	1
Undela, K	1
Srikanth, MS	1
Kumar, TMP	1
Maertens, J	2
Lodewyck, T	1
Donnelly, JP	2
Chantepie, S	1
Robin, C	1
Blijlevens, N	1
Turlure, P	1
Selleslag, D	1
Baron, F	1
Aoun, M	1
Heinz, WJ	1
Bertz, H	6
Ráčil, Z	1
Vandercam, B	1
Drgona, L	1
Coiteux, V	1
Llorente, CC	1
Schaefer-Prokop, C	1
Paesmans, M	1
Ameye, L	1
Meert, L	1
Cheung, KJ	1
Hepler, DA	1
Loeffler, J	1
Barnes, R	1
Marchetti, O	1
Verweij, P	1
Lamoth, F	1
Bochud, PY	1
Schwarzinger, M	1
Cordonnier, C	1
Horgan, MD	1
Alexander, AB	1
Innis, C	1
Stacy, BA	1
Gai, JJ	1
Pesavento, PA	1
Highland, MA	1
Liguori, BL	1
Norton, TM	1
Wellehan, JFX	1
Ossiboff, RJ	1
Silva, GM	1
de Sousa, BR	1
Torres, KB	1
Neves, RP	1
de Melo, HRL	1
de Lima-Neto, RG	1
Yu, PK	3
Moron-Espiritu, LS	3
Lao, AR	3
Enger, K	3
Tonnar, X	3
Kotter, E	3
Martín-Gómez, MT	1
Salavert Lletí, M	1
Cave, C	1
Ramirez, R	1
High, R	1
Ford, J	1
Raulji, C	1
Beck, J	1
Xie, J	2
Zeng, J	1
Zheng, S	1
Alabi, PE	1
Gautier, C	1
Murphy, TP	1
Gu, X	1
Lepas, M	1
Aimanianda, V	1
Sello, JK	1
Ene, IV	1
Fan, X	1
Dai, RC	1
Yan, XF	1
Tong, ZS	1
Gong, J	1
Panggabean, SD	1
Hustrini, NM	1
Bendary, MM	1
Abd El-Hamid, MI	1
Abousaty, AI	1
Elmanakhly, AR	1
Alshareef, WA	1
Mosbah, RA	1
Alhomrani, M	1
Ghoneim, MM	1
Elkelish, A	1
Hashim, N	1
Alamri, AS	1
Al-Harthi, HF	1
Safwat, NA	1
Sun, L	1
Wan, Z	1
Li, R	2
Yu, J	1
Maboni, G	1
Krimer, P	1
Baptista, R	1
Lorton, A	1
Anderson, C	2
Sanchez, S	1
Fisher, BT	2
Zaoutis, T	1
Dvorak, CC	1
Nieder, M	1
Zerr, D	1
Wingard, JR	6
Callahan, C	1
Villaluna, D	1
Dang, H	1
Esbenshade, AJ	1
Alexander, S	1
Wiley, JM	1
Sung, L	3
Hatvani, L	1
Homa, M	1
Chenthamara, K	1
Cai, F	1
Kocsubé, S	1
Atanasova, L	1
Mlinaric-Missoni, E	1
Manikandan, P	1
Revathi, R	1
Dóczi, I	2
Bogáts, G	1
Narendran, V	1
Büchner, R	1
Vágvölgyi, C	1
Druzhinina, IS	1
Kredics, L	2
Kanda, Y	4
Kimura, SI	1
Iino, M	1
Fukuda, T	2
Sakaida, E	1
Oyake, T	1
Yamaguchi, H	6
Fujiwara, SI	1
Jo, Y	1
Okamoto, A	1
Fujita, H	1
Takamatsu, Y	1
Saburi, Y	1
Matsumura, I	1
Yamanouchi, J	1
Shiratori, S	1
Gotoh, M	2
Nakamura, S	1
Tamura, K	2
de Lange, DW	1
Brüggemann, RJM	1
Saconi, ES	1
de Carvalho, VC	1
de Oliveira, PRD	1
Lima, ALLM	1
Rundjan, L	1
Wahyuningsih, R	1
Oeswadi, CA	1
Marsogi, M	1
Purnamasari, A	1
Telles, JP	1
Ribeiro, VST	1
Kraft, L	1
Tuon, FF	1
Wambaugh, MA	1
Denham, ST	1
Ayala, M	1
Brammer, B	1
Stonhill, MA	1
Brown, JC	1
Jenks, JD	1
Cornely, OA	4
Thompson, GR	1
Hoenigl, M	1
Magalhães, TFF	1
da Silva, CM	1
Dos Santos, LBF	1
Santos, DA	1
Silva, LM	1
Fuchs, BB	1
Mylonakis, E	4
Martins, CVB	1
de Resende-Stoianoff, MA	1
de Fátima, Â	1
Wong, TY	1
Loo, YS	1
Veettil, SK	1
Wong, PS	1
Divya, G	1
Ching, SM	1
Menon, RK	1
Ouf, SA	1
Gomha, SM	1
Eweis, M	1
Ouf, AS	1
Sharawy, IAA	1
Alharbi, SA	1
Sheng, L	1
Shen, Q	1
Wang, J	3
Zhang, X	1
Gao, L	1
Wang, L	2
Song, F	1
Wan, Y	1
Al-Obaidi, M	1
Badali, H	2
Cañete-Gibas, C	1
Patterson, HP	1
Wiederhold, NP	1
Shi, T	1
Wu, L	1
Cai, J	1
Chen, H	1
Pedezzi, R	1
de Biagi Junior, CAO	1
de Freitas, MCC	1
da Rosa-Garzon, NG	1
Cabral, H	1
Demers, EG	1
Stajich, JE	1
Ashare, A	1
Occhipinti, P	1
Hogan, DA	1
Bury, D	1
Tissing, WJE	1
Muilwijk, EW	1
Wolfs, TFW	1
Khalid, A	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)[NCT01307579]	Phase 3	517 participants (Actual)	Interventional	2011-04-04	Completed
Oral Nystatin Prophylaxis to Prevent Systemic Fungal Infection in Very Low Birth Weight Preterm Infants: a Randomized Controlled Trial[NCT03390374]	Phase 4	95 participants (Actual)	Interventional	2010-10-31	Completed
Randomized, Open Label, Non-inferiority Study of Micafungin Versus Fluconazole for the Korean Prevention of Invasive Fungal Disease in Living Donor Liver Transplant Recipients[NCT01974375]	Phase 3	172 participants (Anticipated)	Interventional	2012-08-31	Recruiting
A Randomized, Open Label Parallel Controlled, Multicenter Study to Evaluate Safety and Efficacy of Posaconazole Oral Suspension Vs. Fluconazole (Capsule) in High-risk Leukopenic Patients for Prevention of Invasive Fungal Infection[NCT00811928]	Phase 3	252 participants (Actual)	Interventional	2008-11-30	Completed
A Randomized Double-blind Trial of Fluconazole Versus Voriconazole for the Prevention of Invasive Fungal Infections in Allogeneic Blood and Marrow Transplant Patients (BMT CTN #0101)[NCT00075803]	Phase 3	600 participants (Actual)	Interventional	2003-11-30	Completed
Anidulafungin Versus Fluconazole for the Prevention of Invasive Fungal Infections in High-risk Liver Transplant Recipients: a Randomized, Double-blind Trial[NCT00841971]	Phase 4	200 participants (Actual)	Interventional	2010-02-28	Completed
Collection of Granulocytes by Apheresis of Healthy Donors Stimulated With Filgrastim (G-CSF) and Dexamethasone[NCT01553214]	Phase 4	1,000 participants (Anticipated)	Interventional	2012-12-31	Recruiting
Invasive Fungal Infections in Patients Following Stem Cell Transplant[NCT04619147]		300 participants (Anticipated)	Observational	2021-01-31	Not yet recruiting
A Randomized Trial of Tamoxifen Combined With Amphotericin B and Fluconazole for Cryptococcal Meningitis[NCT03112031]	Phase 2	50 participants (Actual)	Interventional	2017-10-10	Completed
Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itraconazole as Primary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation[NCT01160952]	Phase 2	120 participants (Anticipated)	Interventional	2009-05-31	Recruiting
AMBINEB: Clinical Trial to Evaluate Tolerance and Safety of Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary Aspergillosis in Patients With Acute Myeloid Leukemia and Allogeneic Haematopoietic Progenitor Cell Transplant (A[NCT00391014]	Phase 2	150 participants (Anticipated)	Interventional	2006-01-31	Completed
Evaluation of Antifungal Prophylaxis Against Invasive Fungal Infections During Corticosteroid Containing Therapy for Graft-versus-host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation[NCT01282879]	Phase 4	36 participants (Actual)	Interventional	2009-12-31	Terminated (stopped due to In interim analysis, this study met the primary hypothesis.)
Blood and Marrow Transplant Clinical Research Network[NCT00023530]		0 participants	Interventional	2001-09-30	Completed
A Phase II Trial to Evaluate the Safety and Tolerability of Nebulised Amphotericin B Lipid Complex (ABELCET®) in the Prophylaxis of Invasive Pulmonary Aspergillosis During Prolonged Neutropenia in Paediatric Patients With Acute Leukaemia[NCT01615809]	Phase 2	32 participants (Actual)	Interventional	2011-10-31	Completed
[NCT00034645]	Phase 3	600 participants (Actual)	Interventional	1999-01-31	Completed
A Randomized Controlled Trial of Posaconazole (SCH 56592) vs. Standard Azole Therapy for the Prevention of Invasive Fungal Infections Among High-Risk Neutropenic Patients[NCT00044486]	Phase 3	602 participants (Actual)	Interventional	2002-07-31	Completed
Revision of Antifungal Strategies Definitions for Invasive Fungal Infections (Proven/Probable/Possible) in Patients With Hematological Malignancies (REDEFI-SEIFEM)[NCT04024995]		513 participants (Actual)	Observational [Patient Registry]	2019-09-01	Completed
Pharmacokinetics of a Fluconazole Loading Dose in Infants and Toddlers[NCT00797420]	Phase 1	13 participants (Actual)	Interventional	2008-11-30	Completed
Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081)[NCT00000676]	Phase 3	500 participants	Interventional		Completed
Fluconazole Prophylaxis of Thrush in AIDS[NCT00001542]	Phase 4	80 participants	Interventional	1996-07-31	Completed
ANTIVORIFUNGOL:Strategy of Antifungal Use in Oncohematological Neutropenic Patients. Use of Voriconazole as Early Treatment.[NCT00386802]	Phase 4	115 participants (Anticipated)	Interventional	2006-08-31	Completed
An Open Intravenous Multiple Dose, Multi-Center Study to Investigate the Pharmacokinetics, Safety and Toleration of Voriconazole in Children Aged 2-12 Years Who Require Treatment for the Prevention of Systemic Fungal Infection[NCT00005912]	Phase 1	48 participants	Interventional	2000-06-30	Completed
Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia[NCT00001790]	Phase 1	120 participants	Interventional	1998-10-31	Completed
A Pilot Study to Determine the Safety and Clinical Efficacy of Once-Weekly Inhaled AmBisome for the Prevention of Aspergillus Colonization in Lung Transplant Recipients[NCT01254708]	Phase 2	4 participants (Anticipated)	Interventional	2012-01-31	Suspended (stopped due to Study has been placed on hold due to unavailability of funding.)
Evaluation of Caspofungin or Micafungin as Empiric Antifungal Therapy in Adult Patients With Persistent Febrile Neutropenia: A Retrospective, Observational, Sequential Cohort Analysis[NCT00723073]		323 participants (Actual)	Observational	2008-01-31	Completed
Short Daily Alcohol Locks for the Prevention of Tunneled Catheter Infection in Patients With Haematological Disease. Randomised Placebo Controlled Trial[NCT00122642]	Phase 2/Phase 3	440 participants (Anticipated)	Interventional	2005-08-31	Completed
Effect of Fluconazole, Clarithromycin, and Rifabutin on the Pharmacokinetics of Sulfamethoxazole and Dapsone and Their Hydroxylamine Metabolites[NCT00000826]	Phase 1	48 participants	Interventional		Completed
A Randomized Comparative Trial of Zidovudine (AZT) Versus 2',3'-Dideoxyinosine (ddI) Versus AZT Plus ddI in Symptomatic HIV-Infected Children[NCT00000637]	Phase 3	819 participants	Interventional		Completed
A Randomized Trial of Three Anti-Pneumocystis Agents Plus Zidovudine for the Primary Prevention of Serious Infections in Patients With Advanced HIV Infection[NCT00000991]	Phase 3	600 participants	Interventional		Completed
A Phase III, Randomized, Double-Blind, Comparative Trial of FK463 Versus Fluconazole for Prophylaxis of Fungal Infections in Patients Undergoing a Hematopoetic Stem Cell Transplant[NCT00001937]	Phase 3	800 participants	Interventional	1999-11-30	Completed
A Randomized, Double-blind, Placebo Controlled Trial of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in High-risk Adults in the Critical Care Setting[NCT00520234]	Phase 4	222 participants (Actual)	Interventional	2007-08-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Kaplan Meier method will be used to estimate overall survival. Time to event is from enrollment to date of death (by any cause). Participants are censored at last contact or 2 years anniversary of enrollment into this study, whichever occurred first. (NCT01307579)
Timeframe: Up to 2 years post enrollment

Percentage of Participants That Need Empiric Antifungal Therapy

Intervention	Percentage of participants (Number)
Arm I (Caspofungin Acetate)	68.8
Arm II (Fluconazole)	70.8

The percentage of participants requiring empiric antifungal therapy will be determined based on the presence of prolonged fever and neutropenia during each neutropenia course. (NCT01307579)
Timeframe: Up to 5 months since enrollment

Percentage of Participants With Proven or Probable Invasive Aspergillosis (IA)

Intervention	Percentage of participants (Number)
Arm I (Caspofungin Acetate)	71.9
Arm II (Fluconazole)	69.5

Proven or probable invasive aspergillosis (IA) is defined according to the criteria developed by the EORTC/MSG. Kaplan Meier approach will used to estimate the incidence. (NCT01307579)
Timeframe: Up to 5 months since enrollment

Percentage of Participants With Proven or Probable Invasive Fungal Infections (IFI)

Intervention	Percentage of participants (Number)
Arm I (Caspofungin Acetate)	0.5
Arm II (Fluconazole)	3.1

Proven or probable IFI is defined according to criteria developed by the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG). (NCT01307579)
Timeframe: Up to 5 months since enrollment

Number of Participants in Whom All-cause Mortality Occurred Within 100 Days From Randomization

Number of Participants in Whom Mortality is Unlikely, Possibly, and Probably Related to Fungal Infection Occurred Within 100 Days From Randomization

Intervention	Percentage of participants (Number)
Arm I (Caspofungin Acetate)	3.1
Arm II (Fluconazole)	7.2

Intervention	participants (Number)
Posaconazole	3
Fluconazole	8

"Exact Causes of Death and Their Relationship to IFI Episode Were As Follows:~Unlikely related: participant completed treatment and cause of death was due to primary disease or complication~Possibly related: IFI undergoing treatment without stabilization, or with failure to have a complete remission, where cause of death might have been due to IFI, including progression or relapse of primary disease~Probably related: autopsy or clinical signs suggested that progression of IFI was the probable cause of death" (NCT00811928)
Timeframe: From randomization date to Day 100

Number of Participants With Clinical Failure During Treatment

Intervention	participants (Number)
Posaconazole	0
Fluconazole	0

"Clinical failure was defined as follows:~Presence of a proven or probable IFI~Systemic antifungal treatment (IV) for 4 consecutive days or more than 10 days total~Discontinuation due to adverse event (AE) possibly or probably related to study drug~Lost-to-follow-up or discontinuation from the study for any reason with loss to follow-up during the Treatment Phase" (NCT00811928)
Timeframe: Up to 12 weeks (84 days)

Number of Participants With Proven or Probable Diagnosis of IFI Within 100 Days From Randomization

Intervention	participants (Number)
Posaconazole	37
Fluconazole	51

Number of participants who developed a proven or probable IFI from randomization date to Day 100 of follow-up visit. IFI diagnosis criteria may include: persistent fever, failure of appropriate broad-spectrum antibiotic treatment concomitant with lower respiratory tract infection symptoms, microbiological criteria with corresponding clinical signs and symptoms. (NCT00811928)
Timeframe: From randomization date to Day 100

Number of Participants With Proven or Probable Diagnosis of Invasive Fungal Infection (IFI) During the Treatment Period

Intervention	participants (Number)
Posaconazole	5
Fluconazole	16

Number of participants developing a proven or probable IFI from randomization to the last dosage date (up to 12 weeks [84 days]) plus 7 days. IFI diagnosis criteria may include: persistent fever, failure of appropriate broad-spectrum antibiotic treatment concomitant with lower respiratory tract infection symptoms, microbiological criteria with corresponding clinical signs and symptoms. (NCT00811928)
Timeframe: Up to 12 Weeks (84 days) plus 7 days

Time From Randomization to Administration of First Systemic Antifungal Intravenous (IV) Therapy

Intervention	participants (Number)
Posaconazole	4
Fluconazole	11

The time measured in days from randomization to the administration of the first concomitant systemic anti-fungal therapy in the entire FAS population. Not all participants who accepted systemic anti-fungal therapy may have had a IFI clinical diagnosis. IFI diagnosis criteria for antifungal therapy administration may include: persistent fever, failure of appropriate broad-spectrum antibiotic treatment concomitant with lower respiratory tract infection symptoms, microbiological criteria with corresponding clinical signs and symptoms. (NCT00811928)
Timeframe: Up to 12 weeks (84 days)

Time From Randomization to the First Onset of Proven or Probable IFI

Intervention	Days (Number)
Posaconazole	4
Fluconazole	1

The time measured in days to the first occurrence of proven/probable IFI diagnosis in the entire FAS population from randomization to Day 100 of follow-up visit. Participants may not have accepted immediate antifungal treatment and later received antifungal treatment based upon further investigator review of the participant's IFI condition. IFI diagnosis criteria may include: persistent fever, failure of appropriate broad-spectrum antibiotic treatment concomitant with lower respiratory tract infection symptoms, positive blood/biopsy cultures with corresponding clinical signs and symptoms. (NCT00811928)
Timeframe: From randomization date to Day 100

Failure to Engraft

Frequency of Invasive Fungal Infections (IFI)

Intervention	Days (Number)
Posaconazole	8
Fluconazole	2

Intervention	participants (Number)
Fluconazole	11
Voriconazole	9

Incidence of proven, probably, or presumptive IFI (NCT00075803)
Timeframe: 1 year

Frequency of Use of Amphotericin B or Caspofungin

Fungal-free Survival (Percentage of Participants Alive and Free From Proven, Probable, or Presumptive Invasive Fungal Infection) at 180 Days Post-transplant

Duration of Use of Amphotericin B or Caspofungin

Freedom From Possible, Presumptive, Probable, or Proven Invasive Fungal Infection, Death, or Withdrawal of Study Drug Due to Toxicity, Intolerance, or an Empirical Trial of Amphotericin B or Caspofungin Greater Than 14 Consecutive Days

Overall Survival

Percentage of Patients With Invasive Fungal Infection at 100, 180, and 365 Days

Relapse Free Survival

Time to and Severity of Acute and Chronic Graft vs Host Disease (GVHD)

Utility of Galactomannan Assay in Diagnosis of Aspergillus and Response to Therapy

Intervention	percentage of patients (Number)
Fluconazole	13.7
Voriconazole	12.7

Intervention	percentage of patients (Number)
Fluconazole	30.2
Voriconazole	24.1

Intervention	percentage of patients (Number)
Fluconazole	74.9
Voriconazole	78.2

Intervention	days (Mean)
	Number of days on study drug	Start day of empiric antifungal therapy	Days of empiric antifungal therapy
Fluconazole	91	16	7
Voriconazole	96	12	7

Intervention	participants (Number)
	IFI after relapse/progression	IFI before engraftment	IFI who had failure to engraft	IFI after aGVHD (grades II-IV)	IFI while on study drug (up to day 100)	IFI after premature withdrawal of study drug	IFI after start other prophylaxis (not study drug)	IFI after empiric therapy
Fluconazole	2	12	2	11	19	11	8	13
Voriconazole	8	8	1	14	10	16	11	12

Intervention	percentage of patients (Number)
	100 days	180 days	365 days
Fluconazole	85.4	80.0	70.2
Voriconazole	90.1	81.2	67.8

Intervention	percentage of patients (Number)
	100 days	180 days	365 days
Fluconazole	9.5	11.2	13.7
Voriconazole	5.6	7.3	12.7

Intervention	percentage of patients (Number)
	100 days	180 days	365 days
Fluconazole	83.1	74.9	63.3
Voriconazole	86.1	73.9	61.2

Intervention	participants (Number)
	Acute GVHD grade II-IV at day 100	Acute GVHD grade III-IV at day 100	Chronic GVHD at 1 year
Fluconazole	132	42	138
Voriconazole	116	27	137

Although there were 82 Galactomannan (GM) positives, 4 were excluded due to piperacillin/tazobactam administration, without other documentation of IFI, and were deemed false positives. (NCT00075803)
Timeframe: 1 year

Frequency of Fungal Infection

Need for Additional Antifungal Therapy

Efficacy of Primary Prophylaxis With Nebulized Abelcet® on the Incidence of Invasive Pulmonary Aspergillosis

Intervention	participants (Number)
	GM+	GM-
Fluconazole	43	252
Voriconazole	35	270

Intervention	participants (Number)
Anidulafungin	5
Fluconazole	8

Intervention	participants (Number)
Anidulafungin	11
Fluconazole	11

The incidence of invasive pulmonary aspergillosis during the Abelcet® prophylactic treatment period was assessed by the relation between the number of patients with invasive pulmonary aspergillosis and the number of paediatric patients on prophylaxis with Acute Leukaemia (AL) undergoing intensive chemotherapy. (NCT01615809)
Timeframe: at the Baseline visit (week 1) and at the end of the profilaxis treatment phase, up to 6 weeks

Invasive Pulmonary Aspergillosis -Related Mortality During Primary Prophylaxis With Abelcet®.

Intervention	participants (Number)
Amphotericin B (ABELCET®)	3

Percentage of deaths related to Invasive Pulmonary Aspergillosis during the prophylactic treatment period with Abelcet® in paediatric patients with Acute Leukaemia undergoing intensive chemotherapy. (NCT01615809)
Timeframe: at the Baseline visit (week 1) and at the end of the profilaxis treatment phase, up to 6 weeks

Number of Participants With Adverse Events That Results in the Interruption of Treatment, as a Measure of Safety and Tolerability

Intervention	percentage of deaths (Number)
Amphotericin B (ABELCET®)	0

is assessed by the proportion of patients who discontinue prophylactic treatment with Abelcet® due to an adverse event that is related or not to the study drug or for intolerability to it. The last week of treatment will have a different calendar for each participant, depending on the number of cicles needed by each patient (it has been anticipated up to 5 cicles of 2-6 weeks each). (NCT01615809)
Timeframe: at the Baseline visit (week 1) and during the Last week of treatment, up to 6 weeks

Duration of Echinocadin Therapy for Persistent Febrile Neutropenia (FN)

Intervention	participants (Number)
Amphotericin B (ABELCET®)	0

median duration of therapy with an echinocandin (caspofungin or micafungin) for persistent febrile neutropenia (FN) (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007

Duration of Hospitization

Intervention	days (Median)
Caspofungin Arm	10
Micafungin Arm	9

Median number of days patients were hospitalized during the study period (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007

Duration of Neutropenia

Intervention	days (Median)
Caspofungin Arm	29
Micafungin Arm	28

Median number of days patients were neutropenic during the study period (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007

Absence of Any Breakthrough Invasive Fungal Disease (IFD)

Intervention	days (Median)
Caspofungin Arm	20
Micafungin Arm	17

a breakthrough invasive fungal disesase was defined as any fungal infection that was diagnosed > 3 days on or during therapy or within 7 days after completion of therapy with an echinocandin (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007

Composite Primary Endpoint: Number of Participants With an Overall Favorable Response to Echinocandin Therapy for Empiric Antifungal Therapy for Persistent Febrile Neutropenia (FN)

Intervention	participants (Number)
	No breakthrough IFD	Breakthrough IFD
Caspofungin Arm	133	16
Micafungin Arm	153	21

Overall favorable response was defined as achievement of successful treatment of baseline fungal infections, survival to hospital discharge, absence of breakthrough Ivasive fungal disese (IFD), and lack of advserse events (AE) attributable to treatment that led to discontinuation of echinocandin therapy. (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007

Lack of an Adverse Drug Event (ADE) Attributable to Echinocandin (EC) Therapy That Led to Discontinuation of Therapy

Intervention	participants (Number)
	Yes	No
Caspofungin Arm	122	27
Micafungin Arm	141	33

Defined as any advsere event directly attributable to echinocandin treatment that led to discontinuation of therapy or switch to alternative therapy (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007

Liver Function Tests (LFTs) Elevated During or After Echinocandin Therapy

Intervention	participants (Number)
	No ADE	ADE which caused EC therapy discontinuation
Caspofungin Arm	146	3
Micafungin Arm	172	2

aspartate aminotransferase (AST) or alanine aminotransferase (ALT)> 5x the upper limit of normal (ULN) or total bilirubin > 3x the upper limit of normal (ULN) (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007

Mortality at Hospital Discharge

Intervention	participants (Number)
	No LFT elevations	AST > 5x upper limit of normal	ALT > 5x upper limit of normal	Total Bilirubin >3x upper limit of normal
Caspofungin Arm	110	14	10	15
Micafungin Arm	132	15	9	18

We assessed all patients in the study cohort who dischaged from the hospital alive (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007

Specific Type of Adverse Event That Resulted in Echinocandin (EC) Therapy Discontinuation

Intervention	participants (Number)
	Alive at hospital discharge	Died before hospitial discharge
Caspofungin Arm	137	12
Micafungin Arm	161	13

The description of the adverse event that resulted in discontinuation of echinocandin (EC) therapy (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007

Successful Treatment of Any Baseline Invasive Fungal Disease (IFD)

Intervention	participants (Number)
	No Adverse Event requiring EC discontinuation	Rash	Liver function Test (LFT) increase	Anaphylaxis
Caspofungin Arm	146	2	0	1
Micafungin Arm	172	1	1	0

Possible or proven baseline invasive fungal disease were defined as were diagnosed within the 2 days of initiating echinocandin therapy for persistent febrile neutropenia (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007

Proven and Probable Invasive Candidiasis Based on Modified Mycoses Study Group/European Organization for Research and Treatment of Cancer (MSG/EORTC) Criteria.

Intervention	participants (Number)
	No Baseline IFD	Successfully treated baseline IFD	Unsuccessfully treated baseline IFD
Caspofungin Arm	146	2	1
Micafungin Arm	168	4	2

Modified MSG/EORTC criteria for the diagnosis of fungal infections: Proven invasive candidiasis is defined as candidemia, Candida cultured from a sterile site, or histopathological evidence of candida infection. Probable invasive candidiasis is defined as 2 consecutive positive beta glucan levels in the presence of signs and symptoms of infection. (NCT00520234)
Timeframe: Within 7 days after end of therapy

fluconazole and Mycoses

Research Excerpts

Research

Studies (735)

Authors

Clinical Trials (31)

Trial Overview

Trial Outcomes

Overall Survival

Percentage of Participants That Need Empiric Antifungal Therapy

Percentage of Participants With Proven or Probable Invasive Aspergillosis (IA)

Percentage of Participants With Proven or Probable Invasive Fungal Infections (IFI)

Number of Participants in Whom All-cause Mortality Occurred Within 100 Days From Randomization

Number of Participants in Whom Mortality is Unlikely, Possibly, and Probably Related to Fungal Infection Occurred Within 100 Days From Randomization

Number of Participants With Clinical Failure During Treatment

Number of Participants With Proven or Probable Diagnosis of IFI Within 100 Days From Randomization

Number of Participants With Proven or Probable Diagnosis of Invasive Fungal Infection (IFI) During the Treatment Period

Time From Randomization to Administration of First Systemic Antifungal Intravenous (IV) Therapy

Time From Randomization to the First Onset of Proven or Probable IFI

Failure to Engraft

Frequency of Invasive Fungal Infections (IFI)

Frequency of Use of Amphotericin B or Caspofungin

Fungal-free Survival (Percentage of Participants Alive and Free From Proven, Probable, or Presumptive Invasive Fungal Infection) at 180 Days Post-transplant

Duration of Use of Amphotericin B or Caspofungin

Freedom From Possible, Presumptive, Probable, or Proven Invasive Fungal Infection, Death, or Withdrawal of Study Drug Due to Toxicity, Intolerance, or an Empirical Trial of Amphotericin B or Caspofungin Greater Than 14 Consecutive Days

Overall Survival

Percentage of Patients With Invasive Fungal Infection at 100, 180, and 365 Days

Relapse Free Survival

Time to and Severity of Acute and Chronic Graft vs Host Disease (GVHD)

Utility of Galactomannan Assay in Diagnosis of Aspergillus and Response to Therapy

Frequency of Fungal Infection

Need for Additional Antifungal Therapy

Efficacy of Primary Prophylaxis With Nebulized Abelcet® on the Incidence of Invasive Pulmonary Aspergillosis

Invasive Pulmonary Aspergillosis -Related Mortality During Primary Prophylaxis With Abelcet®.

Number of Participants With Adverse Events That Results in the Interruption of Treatment, as a Measure of Safety and Tolerability

Duration of Echinocadin Therapy for Persistent Febrile Neutropenia (FN)

Duration of Hospitization

Duration of Neutropenia

Absence of Any Breakthrough Invasive Fungal Disease (IFD)

Composite Primary Endpoint: Number of Participants With an Overall Favorable Response to Echinocandin Therapy for Empiric Antifungal Therapy for Persistent Febrile Neutropenia (FN)

Lack of an Adverse Drug Event (ADE) Attributable to Echinocandin (EC) Therapy That Led to Discontinuation of Therapy

Liver Function Tests (LFTs) Elevated During or After Echinocandin Therapy

Mortality at Hospital Discharge

Specific Type of Adverse Event That Resulted in Echinocandin (EC) Therapy Discontinuation

Successful Treatment of Any Baseline Invasive Fungal Disease (IFD)

Proven and Probable Invasive Candidiasis Based on Modified Mycoses Study Group/European Organization for Research and Treatment of Cancer (MSG/EORTC) Criteria.

Subjects Who Discontinue Study Therapy Due to a Drug-related Adverse Event

Subjects With 1 or More Serious Drug-related Adverse Event(s)

Reviews

Trials

Other Studies